Agile Therapeutics (AGXRW) 10-K 30 Mar 22 2021 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Mar. 25, 2022	Jun. 30, 2021
Document and Entity Information
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	001-36464
Entity Registrant Name	AGILE THERAPEUTICS INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	23-2936302
Entity Address, Address Line One	500 College Road East, Suite 310
Entity Address, City or Town	Princeton
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08540
City Area Code	609
Local Phone Number	683-1880
Title of 12(b) Security	Common stock
Trading Symbol	AGRX
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 101.2
Entity Common Stock, Shares Outstanding		134,616,862
Entity Central Index Key	0001261249
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Amendment Flag	false
Auditor Name	Ernst & Young LLP
Auditor Firm ID	42
Auditor Location	Iselin, New Jersey

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 19,143	$ 14,463
Marketable securities	0	40,008
Accounts receivable, net	1,533	865
Inventory, net	966
Prepaid expenses and other current assets	2,283	1,449
Total current assets	23,925	56,785
Property and equipment, net	12,447	14,243
Right of use asset	949	138
Other non-current assets	2,012	1,896
Total assets	39,333	73,062
Current liabilities:
Long-term debt, current portion	16,833
Accounts payable	8,707	3,867
Accrued expenses	3,563	3,348
Lease liability, current portion	175	138
Total current liabilities	29,278	7,353
Lease liability, long-term	784
Long-term debt		16,381
Total liabilities	30,062	23,734
Commitments and contingencies (Note 11)
Stockholders' equity
Common stock, $.0001 par value, 150,000,000 shares authorized, 121,396,033 and 87,563,753 issued and outstanding at December 31, 2021 and December 31, 2020, respectively	12	9
Additional paid-in capital	396,376	361,539
Accumulated other comprehensive income		3
Accumulated deficit	(387,117)	(312,223)
Total stockholders' equity	9,271	49,328
Total liabilities and stockholders' equity	$ 39,333	$ 73,062

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Balance Sheets
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	121,396,033	87,563,753
Common stock, outstanding (in shares)	121,396,033	87,563,753

Statements of Operations

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statements of Operations
Revenues, net	$ 4,101	$ 749
Cost of product revenues	10,718	282
Gross profit (loss)	(6,617)	467
Operating expenses:
Research and development	6,246	13,500	$ 9,858
Selling and marketing	43,444	23,285	1,085
General and administrative	14,698	12,735	7,915
Total operating expenses	64,388	49,520	18,858
Loss from operations	(71,005)	(49,053)	(18,858)
Other income (expense)
Interest income	25	309	252
Interest expense	(3,914)	(3,109)
Total other income (expense), net	(3,889)	(2,800)	252
Net loss	$ (74,894)	$ (51,853)	$ (18,606)
Net loss per share (basic) (in dollars per share)	$ (0.77)	$ (0.61)	$ (0.38)
Net loss per share (diluted) (in dollars per share)	$ (0.77)	$ (0.61)	$ (0.38)
Weighted-average common shares (basic) (in shares)	97,072,847	84,683,084	49,432,487
Weighted-average common shares (diluted) (in shares)	97,072,847	84,683,084	49,432,487
Comprehensive loss:
Net loss	$ (74,894)	$ (51,853)	$ (18,606)
Other comprehensive income:
Unrealized loss on marketable securities	(3)	3
Comprehensive loss	$ (74,897)	$ (51,850)	$ (18,606)

Statements of Changes in Stockh

Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Common stockPublic offering	Common stockPrivate Placement	Common stockAt-the-market sales	Common stock	Additional Paid in Capital.Public offering	Additional Paid in Capital.Private Placement	Additional Paid in Capital.At-the-market sales	Additional Paid in Capital.Cumulative Effect, Period of Adoption, Adjusted Balance [Member]	Additional Paid in Capital.	Accumulated Other Comprehensive IncomePublic offering	Accumulated Other Comprehensive Income	Accumulated DeficitCumulative Effect, Period of Adoption, Adjusted Balance [Member]	Accumulated Deficit	Public offering	Private Placement	At-the-market sales	Total
Balance at Dec. 31, 2018				$ 3					$ 261,722				$ (241,551)				$ 20,174
Balance (in shares) at Dec. 31, 2018				34,377,329
Increase (decrease) in stockholders' equity
Share-based compensation - stock options and RSUs									1,762								1,762
Issuance of common stock	$ 2	$ 1	$ 1		$ 12,685	$ 7,809	$ 21,753							$ 12,687	$ 7,810	$ 21,754
Issuance of common stock (in shares)	14,526,315	8,426,750	12,242,436
Issuance of common stock upon exercise of options									164								164
Issuance of common stock upon exercise of options (in shares)				92,271
Vesting of RSUs (in shares)				145,204
Net loss													(18,606)				(18,606)
Balance at Dec. 31, 2019				$ 7				$ 213	306,108			$ (213)	(260,370)				45,745
Balance (in shares) at Dec. 31, 2019				69,810,305
Increase (decrease) in stockholders' equity
Share-based compensation - stock options and RSUs									2,818								2,818
Issuance of common stock	$ 2				48,433									48,435
Issuance of common stock (in shares)	17,250,000
Issuance of common stock upon exercise of options									610								610
Issuance of common stock upon exercise of options (in shares)				503,448
Warrants issued in connection with long-term debt									3,570								3,570
Unrealized net gain on marketable securities										$ 3				3			3
Net loss													(51,853)				(51,853)
Balance at Dec. 31, 2020				$ 9					361,539		$ 3		(312,223)				49,328
Balance (in shares) at Dec. 31, 2020				87,563,753
Increase (decrease) in stockholders' equity
Share-based compensation - stock options and RSUs									3,338								3,338
Issuance of common stock	$ 3				$ 21,078		$ 9,266							$ 21,081		$ 9,266
Issuance of common stock (in shares)	26,666,648		6,915,151
Issuance of common stock upon exercise of options									75								75
Issuance of common stock upon exercise of options (in shares)				126,400
Vesting of RSUs																	(3)
Vesting of RSUs (in shares)				124,081
Warrants issued in connection with long-term debt									1,080								1,080
Unrealized net gain on marketable securities											$ (3)						(3)
Net loss				$ 0					0				(74,894)				(74,894)
Balance at Dec. 31, 2021				$ 12					$ 396,376				$ (387,117)				$ 9,271
Balance (in shares) at Dec. 31, 2021				121,396,033

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (74,894,000)	$ (51,853,000)	$ (18,606,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Noncash inventory reserve	5,323,000
Depreciation	2,064,000	105,000	18,000
Amortization	159,000	171,000	145,000
Noncash stock-based compensation	3,338,000	2,818,000	1,762,000
Noncash interest	1,661,000	1,341,000
Changes in operating assets and liabilities:
Accounts receivable	(668,000)	(865,000)
Inventory	(6,289,000)
Prepaid expenses and other assets	(967,000)	(2,485,000)	(233,000)
Accounts payable and accrued expenses	5,202,000	3,641,000	1,377,000
Lease liability	(131,000)	(184,000)	(152,000)
Net cash used in operating activities	(65,202,000)	(47,311,000)	(15,689,000)
Cash flows from investing activities:
Purchases of marketable securities		(54,837,000)
Sales and maturities of marketable securities	39,729,000	14,500,000
Acquisition of property and equipment	(269,000)	(353,000)	(98,000)
Net cash provided by (used in) investing activities	39,460,000	(40,690,000)	(98,000)
Cash flows from financing activities:
Proceeds from issuance of common stock in private placement, net of offering costs			7,810,000
Proceeds from issuance of long-term debt		20,000,000
Debt financing costs paid		(1,059,000)
Proceeds from exercise of stock options	75,000	610,000	164,000
Net cash provided by financing activities	30,422,000	67,985,000	42,415,000
Net increase (decrease) in cash and cash equivalents	4,680,000	(20,016,000)	26,628,000
Cash and cash equivalents, beginning of period	14,463,000	34,479,000	7,851,000
Cash and cash equivalents, end of period	19,143,000	14,463,000	34,479,000
Supplemental disclosure of noncash financing activities
Warrants issued in connection with long-term debt	1,080,000	3,570,000
Operating right-of-use assets obtained in exchange for new operating lease liabilities	969,000
Supplemental cash flow information
Interest paid	2,383,000	2,099,000
Non-cash transactions
Property and equipment purchases included in accounts payable			49,000
Public offering
Cash flows from financing activities:
Proceeds from issuance of common stock, net of offering costs	21,081,000	$ 48,434,000	12,687,000
At-the-market sales
Cash flows from financing activities:
Proceeds from At-the-Market sales of common stock, net of offering costs	$ 9,266,000		$ 21,754,000

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2021
Organization and Description of Business
Organization and Description of Business	1. Organization and Description of Business Nature of Operations Agile Therapeutics, Inc. (“Agile” or the “Company”) was incorporated in Delaware on December 22, 1997. Agile is a women's healthcare company dedicated to fulfilling the unmet health needs of today's women. The Company's activities since inception have consisted principally of raising capital and performing research and development, including development of the Company’s lead product, Twirla. The Company is headquartered in Princeton, New Jersey. The Company’s sole approved product, Twirla ® , also known as AG200-15, is a once-weekly prescription contraceptive patch that received approval from the U.S. Food and Drug Administration, or FDA in February 2020. Substantially all of the Company’s resources are currently dedicated to commercializing Twirla in the United States. The Company has generated minimal product revenue to date and is subject to a number of risks similar to those of other early stage companies, including, but not limited to, dependence on key individuals, the difficulties and uncertainties inherent in the development of commercially usable products, market acceptance of products, protection of proprietary technology, the potential need to obtain additional capital necessary to fund the development of its products, competition from larger companies and compliance with FDA and other government regulations. If the Company does not successfully commercialize any product candidates, it will be unable to generate recurring product revenue or achieve profitability. The Company has incurred operating losses and negative cash flows from operating activities each year since inception. As of December 31, 2021, the Company had an accumulated deficit of approximately $387 million. The Company expects to continue to incur significant operating expenses for the foreseeable future in connection with its ongoing activities, as the Company: ● maintains a sales and marketing infrastructure to support the continued commercialization of Twirla in the United States; ● continues to evaluate additional line extensions for Twirla and initiates development of potential product candidates in addition to Twirla; ● maintains, leverages and expands the Company’s intellectual property portfolio; and ● adds operational, financial and management information systems and personnel, including personnel to support the Company’s product development and future commercialization efforts. ​ The Company has financed its operations to date primarily through the issuance and sale of its common stock in both public and private offerings (see Note 10), private placements of its convertible preferred stock, venture loans, and non-dilutive grant funding. Going Concern As of December 31, 2021, the Company had cash and cash equivalents of $19.1 million and a $4.9 million working capital deficit. The Company’s current liquidity is sufficient to fund operations only into the second quarter of 2022. The Company closely monitors its cash and cash equivalents and will need to raise additional funds to meet its projected operating requirements, including the continued commercialization of Twirla, and exploring the advancement of its existing pipeline and its possible expansion through business development activities. The Company has generated losses since inception, used substantial cash in operations, has a working capital deficit at December 31, 2021 and anticipates it will continue to incur net losses for the foreseeable future. The Company’s future success depends on its ability to obtain additional capital and/or implement various strategic alternatives, and there can be no assurance that any financing can be realized by the Company, or if realized, what the terms of any such financing may be, or that any amount that the Company is able to raise will be adequate. Based upon the foregoing, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern through the 12 months following the date on which this Annual Report on Form 10-K is filed. The Company continues to analyze various alternatives, including refinancing alternatives, asset sales and mergers and acquisitions. The Company’s future success depends on its ability to raise additional capital as discussed above. The Company cannot be certain that these initiatives or raising additional capital, whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will be available to it or, if available, will be on terms acceptable to the Company. If the Company issues additional securities to raise funds, these securities may have rights, preferences, or privileges senior to those of its common stock, and the Company’s current stockholders will experience dilution. If the Company is unable to obtain funds when needed or on acceptable terms, the Company then may be unable to continue the commercialization of Twirla, and may also be required to cut operating costs, and forego future development and other opportunities. The audited financial statements as of December 31, 2021 have been prepared under the assumption that the Company will continue as a going concern for the next 12 months. The Company’s ability to continue as a going concern is dependent upon its uncertain ability to obtain additional capital, reduce expenditures and/or execute on its business plan and successfully launch Twirla. The audited financial statements as of December 31, 2021 do not include any adjustments that might result from the outcome of this uncertainty. If the Company is unable to continue as a going concern, it may have to liquidate its assets and may receive less than the value at which those assets are carried on the financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Polices ​ Basis of Presentation The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented. ​ Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of revenue and expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, revenue recognition, costs of product revenues, the accounting for common stock warrants, stock-based compensation, and accounting for research and development costs. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. ​ Risks and Uncertainties While Twirla has been approved by the FDA, other potential product candidates developed by the Company will require approval from the FDA prior to commercial sales. There can be no assurance that the Company’s other product candidates will receive the required approval. If the Company is denied approval or such approval is delayed, or is unable to obtain the necessary financing to complete development and approval, there could be a material adverse impact on the Company’s financial condition and results of operations. ​ It should be noted that current public health threats could adversely affect the Company’s ongoing or planned business operations. In particular, the ongoing COVID-19 pandemic has resulted in federal, state and local governments and private entities mandating various restrictions, including travel restrictions, access restrictions, restrictions on public gatherings, and stay at home orders. The effect of these orders, government imposed quarantines and measures the Company has taken, such as implementing work-at-home policies, may negatively impact productivity, disrupt the Company’s business and could delay the Company’s commercialization timeline. The Company cannot presently predict the scope and severity of any potential business shutdowns or disruptions, but if the Company or any of the third parties with whom it engages, including personnel at third-party manufacturing facilities and other third parties with whom the Company conducts business, were to experience shutdowns or other business disruptions, the Company’s ability to conduct its business in the manner and on the timeline presently planned could be materially and adversely impacted. It is unknown how long these conditions will last and what the complete effect will be on the Company. While to date we have been able to continue to execute our overall business plan, some of our business activities have been slowed and taken longer to complete and we continue to adjust to the challenges of operating in a largely remote setting with our employees. We have only recently launched our commercial activities for Twirla and begun engaging with healthcare providers to promote Twirla. We expect that, as we broaden our sales detailing activities, in some instances our sales force may encounter challenges engaging with healthcare providers during this on-going pandemic. Although many areas of the United States have begun to re-open access to offices and other commercial facilities, there continue to be areas where restrictions remain in place, which may have the potential to affect our ability to conduct our business. Further, new variants, including those which are more easily transmissible or resistant to existing vaccines, may lead to new shutdowns or business disruptions in the future. The Company will continue to closely monitor events as they develop and evaluate alternative, mitigating measures it can implement if needed. Cash and Cash Equivalents The Company considers all highly-liquid investments with an original maturity of three months or less when purchased to be cash equivalents. All cash and cash equivalents are held in United States financial institutions. Cash and cash equivalents include money market funds that invest primarily in commercial paper and U.S. government and U.S. government agency obligations. The Company maintains balances with financial institutions in excess of the Federal Deposit Insurance Corporation limit. ​ Marketable Securities The Company invests a portion of its excess cash balances in marketable securities, including U.S. government agency securities, and highly rated corporate bonds. The Company classifies all of its marketable securities as current assets on the balance sheet because they are available-for-sale and available to fund current operations. Marketable securities are stated at fair value with unrealized gains and losses included as a component of accumulated other comprehensive income (loss), which is a separate component of stockholders' equity, until such gains and losses are realized. If a decline in the fair value is considered other-than-temporary, based on available evidence, the unrealized loss is reclassified from accumulated other comprehensive income (loss) to the statements of operations. Realized gains and losses are determined on the specific identification method and are included in other income. Trade Accounts Receivable and Allowances Trade accounts receivable are amounts owed to the Company by its customers for product that has been delivered. The trade accounts receivable are recorded at the invoice amount, less prompt pay and other discounts, chargebacks, and an allowance for credit losses, if any. The allowance for credit losses is the Company’s estimate of losses over the life of the receivables. The Company evaluates forward looking economic factors and uses professional judgment to determine the allowance for credit losses. The credit loss reserves are reviewed and adjusted periodically. Credit loss reserves were not material as of December 31, 2021 and 2020, respectively. ​ Trade accounts receivable are aged based on the contractual payment terms. When the collectability of an invoice is no longer probable, the Company will create a reserve for that specific receivable. If a receivable is determined to be uncollectible, it is charged against the general credit loss reserve or the reserve for the specific receivable, if one exists. Fair Value of Financial Instruments In accordance with Accounting Standards Codification (“ASC”) 825, Financial Instruments Other financial instruments, including accounts receivable, accounts payable and accrued liabilities, are carried at cost, which approximates fair value given their short-term nature. Inventory Inventory is valued utilizing the weighted average costing method. The Company records an inventory reserve for losses associated with dated, expired, excess or obsolete items. This reserve is based on management’s current knowledge with respect to inventory levels, planned production and sales volume assumptions. During the year ended December 31, 2021, the Company established a reserve of approximately $5.3 million for inventory not expected to be sold prior to its shelf life date. ​ The Company’s third-party manufacturer, Corium, completed the validation of the commercial manufacturing process for Twirla in the fourth quarter of 2020. The costs associated with validation batches were expensed as research and development expenses during the period the costs were incurred. The Company used this validation product for commercial supplies and samples of Twirla into May 2021. Since the Company did not capitalize any validation product, all sales of this validation product had no associated product cost. During the year ended Dectember 31, 2021, units sold with no associated product cost were approximately 3,000 . Had such inventory been valued at acquisition cost, it would have resulted in an immaterial increase to cost of goods sold and a corresponding decrease to gross profit. ​ Property and Equipment Property and equipment, consisting of office equipment, computer equipment and manufacturing equipment, is stated at cost, less accumulated depreciation. Depreciation is computed using the straight- line method over the estimated useful lives of the assets. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to earnings in the period in which costs are incurred. Improvements and additions are capitalized in accordance with Company policy. ​ Long-Lived Assets In accordance with ASC 360, Property, Plant and Equipment ​ Research and Development Expense Research and development costs are expensed as incurred. Research and development expense consists primarily of costs related to personnel, including salaries and other personnel-related expenses, expenses related to manufacturing, clinical trial expenses, consulting fees and support services used in drug development. All research and development costs are charged to operations as incurred in accordance with ASC 730, Research and Development In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are deferred and are expensed when the activity has been performed or when the goods have been received. ​ Advertising Costs The Company has elected to expense advertising costs when incurred. Advertising costs totaled Deferred Financing Costs Costs directly attributable to the Company’s term loan (see Note 9) are deferred and reported as a reduction of the related term loan. These costs represent legal fees and other costs related to the term loan and are being amortized utilizing the straight-line method over the term of the loan. Amortization of deferred financing costs charged to interest expense was approximately $277,000, $231,000 and $0 for the years ended December 31, 2021, 2020 and 2019, respectively. ​ Concentrations of Credit Risk Financial instruments which potentially subject the Company to credit risk consist principally of cash, cash equivalents and marketable securities. The Company invests its cash, cash equivalents and marketable securities in debt instruments and interest-bearing accounts in United States financial institutions, the balances of which exceed federally insured limits. The Company has not Major customers of the Company are defined as those constituting greater than 10% of its total revenue. In 2021, the Company had sales to customers that individually accounted for more than 10% of our total revenue. These customers had sales of of total revenues in the aggregate. Accounts receivable related to each of these major customers comprised Revenue Recognition The Company recognizes revenue from the sale of its product, Twirla, in accordance with ASC 606, Revenue from Contracts with Customers ​ In accordance with ASC 606, the Company recognizes revenue at the point in time when its performance obligation is satisfied by transferring control of the promised goods or services to a customer. In accordance with the Company’s contracts with customers, control of the product is transferred upon the conveyance of title, which occurs when the product is sold to and received by a customer. The Company’s customers are located in the United States and consist primarily of wholesale distributors. Trade accounts receivable due to the Company from contracts with its customers are stated separately in the balance sheet, net of various allowances as described in the Trade Accounts Receivable and Allowance policy. ​ The amount of revenue recognized by the Company is equal to the amount of consideration that is expected to be received from the sale of product to its customers. Revenue is only recognized when it is probable that a significant reversal will not occur in future periods. To determine whether a significant reversal will occur in future periods, the Company assesses both the likelihood and magnitude of any such potential reversal of revenue. ​ Twirla is sold to customers at the wholesale acquisition cost (WAC). However, the Company records product revenue, net of reserves for applicable variable consideration. These types of variable consideration items reduce revenue and include the following: ​ •Distribution services fees •Prompt pay and other discounts •Product returns •Chargebacks •Rebates •Co-payment assistance ​ An estimate for each variable consideration item is made and is recorded in conjunction with the revenue being recognized. Generally, if the estimated amount is payable to a customer, it is recorded as a reduction to accounts receivable. If the estimated amount is payable to an entity other than a customer, it is recorded as a current liability. An estimated amount of variable consideration may differ from the actual amount. At each balance sheet date, these provisions are analyzed, and adjustments are made if necessary. Any adjustments made to these provisions would affect net product revenue and earnings in the current period. ​ In accordance with ASC 606, the Company must make significant judgments to determine the estimate for certain variable consideration. For example, the Company must estimate the percentage of end-users that will obtain the product through public insurance such as Medicaid or through private commercial insurance. To determine these estimates, the Company relied on industry standard data and trend analysis since historical sales data was not available as Twirla was launched in December 2020. As historical data becomes available, the Company will incorporate that data into its estimates of variable consideration. ​ The specific considerations that the Company uses in estimating these amounts related to variable considerations are as follows. ​ Distribution services fees – The Company pays distribution service fees to its wholesale distributors. These fees are a contractually fixed percentage of WAC and are calculated at the time of sale based on the purchase amount. The Company records these fees as contra trade accounts receivable on the balance sheet. ​ Prompt pay and other discount ​ The Company may also give other discounts to its customers to incentivize purchases and promote customer loyalty. The terms of such discounts may vary by customer. These discounts reduce gross product revenue at the time the revenue is recorded. ​ Product returns ​ Chargebacks ​ Rebates ​ Co-payment assistance ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ Allowances for ​ Payments & ​ December 31, ​ 2020 current period sales credits 2021 Customer credits, discounts and allowances ​ $ 187 ​ $ 825 ​ $ (641) ​ $ 371 Rebates and co-pay assistance ​ ​ 116 ​ ​ 1,055 ​ ​ (502) ​ ​ 669 Total ​ $ 303 ​ $ 1,880 ​ $ (1,143) ​ $ 1,040 ​ Warrants The Company accounts for its warrants to purchase common stock in accordance with ASC 480, Distinguishing Liabilities from Equity . On January 1, 2019, the Company adopted the provisions of Accounting Standards Update (“ASU”) 2017-11 Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception, In connection with entering into a senior secured term loan facility in February 2020, the Company issued warrants to purchase 1,400,000 shares of its common stock. In connection with an amendment to that facility in February 2021, the Company issued a warrant to purchase 450,000 shares of the Company’s common stock. In connection with an underwritten public offering completed in October 2021, the Company issued warrants to purchase 13,333,324 shares of its common stock. This offering also triggered an adjustment to the exercise price of the existing warrants mentioned above, which resulted in a reduction of the strike price for these warrants. This reduction resulted in an immaterial increase to additional paid in capital. S Income Taxes The Company accounts for deferred taxes using the asset and liability method as specified by ASC 740, Income Taxes The Company has adopted the authoritative guidance on accounting for and disclosure of uncertainty in tax positions which prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. The Company has no ​ Stock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC 718, Compensation-Stock Compensation . The Company grants stock options for a fixed number of shares to employees and non-employees with an exercise price equal to the fair value of the shares at grant date. Compensation cost is recognized for all share-based payments granted and is based on the grant-date fair value estimated using the weighted-average assumption of the Black-Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. The Company elects to account for forfeitures when they occur. The equity instrument is not considered to be issued until the instrument vests. As a result, compensation cost is recognized over the requisite service period with an offsetting credit to additional paid-in capital. The Company also awards restricted stock units (“RSUs”) to employees and its board of directors. RSUs are generally subject to forfeiture if employment terminates prior to the completion of the vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. Cost associated with performance-based restricted stock units with a performance condition which affects the vesting is recognized only if the performance condition is probable of being satisfied. ​ Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception. ​ Net Loss Per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, common stock warrants, unvested RSUs and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented. The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share for the years ended December 31, 2021, 2020 and 2019, respectively, because to do so would be anti-dilutive (in common equivalent shares): ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 2019 Common stock warrants ​ 15,183,324 1,400,000 180,274 Unvested restricted stock units ​ 333,290 159,795 — Common stock options ​ 10,367,442 8,519,086 7,192,357 Total ​ 25,884,056 10,078,881 7,372,631 ​ Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures. In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part 1) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. additional paid-in capital. As a result of the adoption of ASU 2017-11, effective January 1, 2019, the Company no longer measures these warrants at fair value. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. ASU 2016-13 was adopted by the Company on January 1, 2020 and had no current impact on the Company as the Company did not have any financial instruments covered by the topic on the date of adoption. In December 2020, the Company recognized its first sales of Twirla resulting in a receivable of $0.9 million at December 31, 2020 and an immaterial allowance for credit losses. As of December 31, 2021, receivables total $1.5 million, and the allowance for credit losses is immaterial. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). This guidance simplifies the accounting for income taxes by, among other things, reducing complexity in the interim-period accounting for year-to-date loss limitations and changes in tax laws. The guidance is effective for the Company on January 1, 2021. The Company is currently evaluating the impact of adopting this standard and does not expect the guidance to have a material impact on its consolidated financial statements. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848), an expansion of ASU 2020-04: Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2021-01”). This guidance permits entities to elect certain optional expedients and exceptions when accounting for derivative contracts and certain hedging relationships affected by changes in the interest rates used for discounting cash flows, for computing variation margin settlements, and for calculating price alignment interest) in connection with reference rate reform activities under way in global financial markets (the “discounting transition”). The guidance was effective immediately and did not have an impact on our consolidated financial statements. ​ Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying financial statements.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2021
Fair Value Measurements
Fair Value Measurements	3. Fair Value Measurements ASC 820, Fair Value Measurements and Disclosures Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: ● Level 1—Quoted prices in active markets for identical assets and liabilities. The Company’s Level 1 assets consist of cash and cash equivalents. The Company has no Level 1 liabilities. ● Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities. The Company has no Level 2 assets or liabilities. ● Level 3—Unobservable inputs that are supported by little or no market data and which require internal development of assumptions about how market participants price the fair value of the assets or liabilities. The Company has no Level 3 assets or liabilities. The following tables set forth the Company’s financial instruments measured at fair value by level within the fair value hierarchy as of December 31, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1 Level 2 Level 3 December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 19,143 ​ $ — ​ $ — Total assets at fair value ​ $ 19,143 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1 Level 2 Level 3 December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 14,463 ​ $ — ​ $ — Marketable securities ​ ​ — ​ ​ 40,008 ​ ​ — Total assets at fair value ​ $ 14,463 ​ $ 40,008 ​ $ — ​ There were no transfers between Level 1, 2 or 3 during 2021 or 2020.

Marketable Securities

Marketable Securities	12 Months Ended
	Dec. 31, 2021
Marketable Securities
Marketable Securities	4. Marketable Securities The Company had no marketable securities as of December 31, 2021. The following is a summary of marketable securities as of December 31, 2020, classified as available-for-sale: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross Unrealized ​ ​ ​ ​ Amortized ​ ​ ​ ​ ​ ​ ​ Fair ​ Cost ​ Gains ​ Losses ​ ​ Value December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ U.S. government obligations (maturing in one year or less) $ 7,035 ​ $ 2 ​ $ — ​ $ 7,037 Corporate debt securities (maturing in one year or less) 32,970 ​ 1 ​ ​ — ​ 32,971 Total marketable securities $ 40,005 ​ $ 3 ​ $ — ​ $ 40,008 ​ The Company holds investment-grade marketable securities. There were no continuous unrealized loss positions in excess of twelve months as of December 31, 2021.

Prepaid Expenses

Prepaid Expenses	12 Months Ended
	Dec. 31, 2021
Prepaid Expenses
Prepaid Expenses	5. Prepaid Expenses Prepaid expenses consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Prepaid insurance ​ $ 775 ​ $ 680 Other ​ 1,508 ​ 769 Total prepaid expenses and other current assets ​ $ 2,283 ​ $ 1,449 ​

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2021
Property and Equipment
Property and Equipment	6. Property and Equipment Property and equipment, consisting of manufacturing, office and computer equipment, is stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Property and equipment consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ Estimated ​ 2021 2020 Life Office equipment ​ $ 7 ​ $ — 5 years Computer equipment ​ 113 ​ — 3 Years Manufacturing equipment ​ 14,477 ​ 14,328 7 years ​ ​ 14,597 ​ 14,328 ​ ​ Less: accumulated depreciation ​ (2,150) ​ (85) Property and equipment ​ $ 12,447 ​ $ 14,243 ​ Upon successful completion of the validation of the commercial manufacturing process for Twirla by the Company’s contract manufacturer, Corium, and the announcement of the commercial launch of Twirla in December 2020, manufacturing equipment with a cost of $14.3 million was placed into service and started being depreciated.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2021
Accrued Liabilities
Accrued Liabilities	7. Accrued Liabilities Accrued liabilities consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Accrued compensation ​ $ 2,086 ​ $ 1,697 Accrued professional fees and other ​ 1,477 ​ 1,651 Total accrued liabilities ​ $ 3,563 ​ $ 3,348 ​

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases
Leases	8. Leases In February 2016, the FASB issued ASU No. 2016-02, Leases . The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of operations. The Company adopted ASU No. 2016-02 on January 1, 2019 for leases that existed on that date. The Company has elected to apply the provisions of ASC 842 modified retrospectively at January 1, 2019 through a cumulative-effect adjustment. Prior period results continue to be presented under ASC 840 based on the accounting standards originally in effect for such periods. The Company has no operating lease for its corporate headquarters in Princeton, NJ. The current lease commenced on December 1, 2021 and terminates on March 31, 2025. The lease provides the Company with an option to extend the lease for an additional five years. Under the terms of the lease, the Company pays base annual rent subject to a fixed dollar amount increase each year, a fixed monthly charge for electricity, and other normal operating expenses such as taxes, repairs, and maintenance. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. The lease does not require variable lease payments, residual value guarantees or restrictive covenants. The lease does not provide an implicit rate, therefore the Company used its incremental borrowing rate as the discount rate when measuring the operating lease liability. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease. Operating lease expense was $180,000 and $190,000 for the years ended December 31, 2021 and 2020, respectively. Operating cash flows used for operating leases during the years ended December 31, 2021 and 2020 were $131,000 and $184,000 respectively. As of December 31, 2021, the weighted-average remaining lease term was 3.25 years and the weighted average discount rate was 11.8%. Future minimum lease payments under non-cancellable leases as of December 31, 2021 were as follows: ​ ​ ​ ​ ​ ​ Year ending December 31, ​ ​ ​ 2022 ​ ​ 277 2023 ​ ​ 390 2024 ​ ​ 398 2025 $ 101 Total ​ $ 1,166 Less: Interest ​ (207) Present value of lease liability ​ $ 959 ​

Credit Agreement and Guaranty

Credit Agreement and Guaranty	12 Months Ended
	Dec. 31, 2021
Credit Agreement and Guaranty
Credit Agreement and Guaranty	9. Credit Agreement and Guaranty million tranche was to be available to the Company based on the achievement of a revenue milestone by December 31, 2021. We did not achieve that milestone and that tranche is no longer available to us. On February 26, 2021 the Perceptive Credit Agreement was amended (“Amended Perceptive Credit Agreement”) by creating a fourth tranche of $10.0 million that will be available based on the achievement of a revenue milestone. We currently do not believe we will achieve the milestone for the fourth tranche of $10.0 million. On January 7, 2022, the Company and Perceptive entered into a second amendment to the Amended Perceptive Credit Agreement (the “Second Amendment”). The Second Amendment waives the Company’s obligations to comply with certain financial covenants relating to minimum revenue requirements through September 30, 2022 and to file financial statements along with its Annual Report on Form 10-K that are not subject to any “going concern” qualification. The effectiveness of the Second Amendment is conditioned upon the satisfaction of certain conditions, including the Company raising additional capital and prepaying a portion of its outstanding debt. On January 7, 2022, the Company prepaid $5.0 million of the outstanding debt, and in accordance with the terms of the Second Amendment, no prepayment premium was due. ​ The facility will mature on February 10, 2024 (“Maturity Date”). The Company is scheduled to make interest-only payments on the loans under the Perceptive Credit Agreement until February 10, 2023. Thereafter, the Company is required to make monthly principal payments in an amount equal to 1.50 % of the principal amount of the outstanding loans until February 10, 2024. ​ Borrowings under the Second Amendment will accrue interest at an annual rate equal to . The rate of interest in effect as of the Closing Date and at December 31, 2021 was 11.75% . Upon the occurrence and during the continuance of any event of default under the Second Amendment, the interest rate automatically increases by 3.0% per annum. ​ The Company may prepay any outstanding loans in whole or in part. Any such prepayment of the loans is subject to a prepayment fee of 8.0% if such prepayment occurs on or prior to February 10, 2022; 4.0% if such prepayment occurs after February 10, 2022 and on or prior to February 10, 2023; and 2.0 % if such prepayment occurs after February 10, 2023 and prior to February 10, 2024. The Company made a prepayment of $5.0 million on January 7, 2022 in connection with the Second Amendment. The prepayment fee was waived by Perceptive. ​ All of the Company’s obligations under the Second Amendment are secured by a first-priority lien and security interest in substantially all of the Company’s tangible and intangible assets, including intellectual property. ​ The Second Amendment contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customary for similar financings. The negative covenants restrict or limit the ability of the Company to, among other things and subject to certain exceptions contained in the Perceptive Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company’s business activities; make certain investments or restricted payments (each as defined in the Amended Perceptive Credit Agreement); change its fiscal year; pay dividends; repay other certain indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting the Company’s ability to make loan repayments under the Amended Perceptive Credit Agreement. In addition, the Company must (i) at all times prior to the Maturity Date maintain a minimum cash balance of $3.0 million; and (ii) as of the last day of each fiscal quarter commencing with the fiscal quarter ending December 31, 2022, report revenues for the trailing 12-month period that exceed the amounts set forth in the Second Amendment, which range from $53.0 million for the fiscal quarter ending December 31, 2022 to $87.1 million for the fiscal quarter ending December 31, 2023. The Company received covenant waivers for the failure to achieve the revenue covenants in 2021 and pertaining to the existence of substantial doubt about the Company’s ability to continue as a going concern as disclosed in Note 1. The Company was in compliance with the remaining covenants under the Second Amendment as of December 31, 2021. ​ In connection with the Perceptive Credit Agreement, the Company issued to Perceptive two warrants to purchase an aggregate of 1,400,000 shares of the Company’s common stock (together, the “Perceptive Warrants”). The first warrant is exercisable for 700,000 shares of common stock at an exercise price of $3.74 per share. The second warrant is exercisable for 700,000 shares of common stock at an exercise price of $4.67 per share. The Perceptive Warrants contain anti-dilution provisions and other warrant holder protections. The Perceptive Warrants are not exercisable to the extent that Perceptive would beneficially own more than 19.99% of the Company’s common stock as a result of the exercise. The Perceptive Warrants expire on February 10, 2027. In connection with the Amended Perceptive Credit Agreement, the Company issued to Perceptive a warrant to purchase 450,000 shares of the Company’s common stock at an exercise price of $2.87 per share. ​ As a result of the public offering of the Company’s common stock completed in October 2021 (see Note 10), the anti-dilution provision of the Perceptive Warrants was triggered resulting in a reduction of the strike price for the Perceptive Warrants. Warrants to purchase 700,000 shares of common stock that had an exercise price of $4.67 per share were reduced to $3.83 per share, warrants to purchase 700,000 shares of common stock that had an exercise price of $3.74 per share were reduced to $3.11 per share, and warrants to purchase 450,000 shares of common stock that had an exercise price of $2.87 per share were reduced to $2.43 per share. ​ The Company allocated the proceeds of $20.0 million in accordance with ASC 470 based on the relative fair values of the debt and warrants. The relative fair value of the warrants of approximately $3.6 million at the time of issuance, which was determined using the Black-Scholes option-pricing model, was recorded as additional paid-in capital and reduced the carrying value of the debt. The significant assumptions used in preparing the option pricing model for valuing the Company’s warrants issued to Perceptive include (i) volatility (70.0%), (ii) risk free interest rate of 1.47% (estimated using treasury bonds with a 3-year life), (iii) strike prices of $3.74 and $4.67 for the common stock warrants, (iv) fair value of common stock ($4.01) and (v) expected life ( 7 years). The fair value of the warrants as well as the debt issue costs incurred in connection with the entry into the Perceptive Credit Agreement, including a facility fee of 1% of the total amount of loans available under the facility, are presented as a direct deduction from the carrying amount of the term loan on the consolidated balance sheet as detailed below. ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ ​ 2021 ​ 2020 Notes payable $ 20,000 ​ $ 20,000 Debt issuance costs ​ ​ (550) ​ ​ (828) Warrant discount ​ ​ (2,617) ​ ​ (2,791) Total debt ​ $ 16,833 ​ $ 16,381 Less, current portion ​ ​ 16,833 ​ ​ — Long-term debt, less current portion ​ $ — ​ $ 16,381 ​ ​ As noted above, the Company obtained a waiver pertaining to the failure to achieve the revenue covenants in 2021. The Company’s future revenue is difficult to predict, and there is no assurance that the Company will be able to obtain additional waivers for any future failures to achieve revenue covenants. Accordingly, the total outstanding debt has been classified as current as of December 31, 2021.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity
Stockholders' Equity	10. Stockholders’ Equity The Company’s Certificate of Incorporation, among other things: (i) authorizes 150,000,000 shares of common stock; (ii) authorizes 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series; (iii) provides that the Board be divided into three classes with staggered three-year terms, with one class of directors to be elected at each annual meeting of the Company’s stockholders; (iv) provides that directors may only be removed with cause and only upon the affirmative vote of holders of at least 75% of the voting power of all then-outstanding shares of capital stock of the Company entitled to vote generally in the election of directors; (v) provides that only the Board, the chairman of the Board or the chief executive officer may call a special meeting of stockholders; and (vi) requires that any action instituted against the Company’s officers or directors in connection with their service to the Company be brought in the State of Delaware. On January 7, 2022, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance from 150,000,000 shares to 300,000,000 shares. Shelf Registration Statements On October 2, 2020, the Company filed a universal shelf registration statement with the SEC for the issuance of common stock, preferred stock, warrants, rights, debt securities and units up to an aggregate amount of $200.0 million (“the 2020 Shelf Registration Statement”). On October 14, 2020, the 2020 Shelf Registration Statement was declared effective by the SEC. In the future, the Company may periodically offer one or more of these securities in amounts, prices and terms to be announced when and if the securities are offered. At the time any of the securities covered by the 2020 Shelf Registration Statement are offered for sale, a prospectus supplement will be prepared and filed with the SEC containing specific information about the terms of any such offering. Prior to the 2020 Shelf Registration Statement, the Company had filed a universal shelf registration statement in November 2018 for the issuance of up to $100.0 million of securities, (“the 2018 Shelf Registration Statement”), which was declared effective by the SEC on November 14, 2018. On January 23, 2019, the Company filed a prospectus supplement to the 2018 Shelf Registration Statement registering an at-the-market offering program entered into for the sale of up to $10.0 million of shares of the Company’s common stock. In the year ended December 31, 2019, the Company sold a total of 1,801,528 shares of the Company’s common stock under the ATM program resulting in net proceeds of approximately $2.5 million. In August 2019, the Company filed a prospectus supplement to the 2018 Shelf Registration Statement registering a public offering of 14,526,315 shares of common stock at a price of $0.95 per share. Proceeds from the public offering, net of underwriting discounts, commissions and offering expenses, were approximately $12.7 million. On November 8, 2019, the Company filed a prospectus supplement to the 2018 Shelf Registration Statement registering an at-the-market offering program entered into for the sale of up to $20.0 million of shares of the Company’s common stock. In the year ended December 31, 2019, the Company sold a total of 10,440,908 shares of common stock under this ATM program, representing all of the capacity, resulting in net proceeds of approximately $19.3 million. On February 21, 2020, the Company filed a prospectus supplement to the 2018 Shelf Registration Statement registering a public offering of 17,250,000 shares of common stock at a price of $3.00 per share. Proceeds from the public offering, net of underwriting discounts, commissions and offering expenses were approximately $48.4 million. On March 18, 2021, the Company filed a prospectus supplement to the 2020 Shelf Registration Statement registering an at-the-market offering program entered into for the sale of up to $50.0 million of shares of the Company’s common stock. In the year ended December 31, 2021, the Company sold a total of 6,915,151 shares of common stock under this ATM program, resulting in net proceeds of approximately $9.3 million. On October 8, 2021, the Company filed a prospectus supplement to the 2020 Shelf Registration Statement registering a public offering of 26,666,648 shares of its common stock and warrants to purchase 13,333,324 shares of its common stock at a combined price of $0.85 per share of common stock and one-half of a warrant to purchase one share of common stock. Proceeds from the public offering, net of underwriting discounts, commissions and offering expenses were approximately $21.1 million. 2,425 shares of Series A convertible preferred stock (the “Series A Preferred Stock”) and 2,425 shares of Series B convertible preferred stock (the “Series B Preferred Stock”) and Series A warrants (the “Series A Warrants”) to purchase up to an aggregate of 24,250,000 shares of the common stock of the Company (the “Common Stock”) and Series B warrants (the “Series B Warrants”) to purchase up to an aggregate of 24,250,000 shares of Common Stock. Each share of Series A Preferred Stock and Series B Preferred Stock has a stated value of $1,000 per share and a conversion price of $0.20 per share. The shares of preferred stock issued in the offering are convertible into an aggregate of 24,250,000 shares of Common Stock . Proceeds from the direct offering, net of the placement agent’s fees and offering expenses were approximately ​ Private Placement In March 2019, the Company completed a private placement of 8,426,750 shares of common stock at $0.93 per share. Proceeds from the Company’s private placement, net of offering costs were approximately $7.8 million. Common Stock Warrants shares of its common stock. These warrants contain anti-dilution provisions that were triggered upon the Company’s public offering that was completed in October 2021. As a result of the offering, warrants to purchase 700,000 shares of common stock that had an exercise price of $4.67 per share were reduced to $3.83 per share, warrants to purchase 700,000 shares of common stock that had an exercise price of $3.74 per share were reduced to $3.11 per share, and warrants to purchase 450,000 shares of common stock that had an exercise price of $2.87 per share were reduced to $2.43 per share. This repricing resulted in an immaterial increase to additional paid-in-capital.

Equity Incentive Plans

Equity Incentive Plans	12 Months Ended
	Dec. 31, 2021
Equity Incentive Plans
Equity Incentive Plans	11. Equity Incentive Plans Stock options The Company had granted stock options under an amended and restated 1997 Equity Incentive Plan (the “1997 Plan”) and a 2008 Equity Incentive Plan (the “2008 Plan”). The plans provided for the granting of incentive and non-statutory options and stock awards to consultants, directors, officers and employees. Such options are exercisable for a period of ten years and generally vest over a four-year period. In conjunction with the adoption of the 2008 Plan in April 2008, no additional grants were made from the 1997 Plan and issued options from the 1997 Plan remain outstanding. In 2014, the Board approved the 2014 Incentive Compensation Plan (the “2014 Plan”). The 2014 Plan is the successor to the Company’s 2008 Plan and 1997 Plan. In conjunction with the adoption of the 2014 Plan in 2014, no additional grants were made from the 2008 Plan and options from the 1997 Plan and the 2008 Plan remain outstanding. In June 2018, the 2014 Plan was amended and restated, and the Amended and Restated 2014 Incentive Compensation Plan is now referred to as the Amended 2014 Plan. As of December 31, 2021, there were 1,507,871 shares available for future grant under the Amended 2014 Plan. Through December 31, 2021, the Company granted options to certain employees and nonemployees to purchase shares of common stock at exercise prices ranging from $0.58 to $10.75 per share. The Company recorded noncash stock-based compensation expense for the years ended December 31, 2021, 2020 and 2019 based on the fair market value of the options and shares granted at the grant date. Stock-based compensation expense was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, ​ 2021 2020 2019 Cost of goods sold ​ $ 271 ​ $ 14 ​ $ — Research and development ​ ​ 490 ​ ​ 651 ​ ​ 522 Selling and marketing ​ ​ 148 ​ ​ 108 ​ ​ — General and administrative ​ 2,429 ​ 2,045 ​ 1,240 Total ​ $ 3,338 ​ $ 2,818 ​ $ 1,762 ​ The following assumptions were used to compute employee stock-based compensation under the Black-Scholes option pricing model: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2021 2020 2019 Risk‑free interest rate .66% - 1.51 % .40% - 1.68 % 1.74% ‑ 2.61 % Expective volatility 105% ‑ 106 % 65% ‑ 106 % 65 % Expected dividend yield 0 % 0 % 0 % Expected life (in years) 6.25 6.25 6.25 ​ ​ Risk-free interest rate. The Company bases the risk-free interest rate assumption on observed interest rates appropriate for the expected term of the stock option grants. Expected dividend yield. The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends. Expected volatility. The expected volatility assumption was based on volatilities of a peer group of similar companies whose share prices are publicly available until August 2020. The peer group was developed based on comparable companies in the biotechnology and pharmaceutical industries. In August 2020, the Company transitioned to its own expected volatility based on sufficient historical data. Expected term. The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historic exercise behavior, management determined the expected life assumption using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period. Forfeitures. As of December 31, 2021, the unrecorded deferred stock-based compensation balance related to stock options was approximately $6.4 million and will be recognized over an estimated weighted-average amortization period of 2.5 years. The weighted average grant date fair value of options granted during the year ended December 31, 2021 was $2.63. The following table summarizes the options outstanding, options vested and the options exercisable as of December 31, 2021, 2020 and 2019: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ Average Remaining ​ ​ ​ ​ ​ ​ Exercise Contractual ​ Aggregate ​ ​ Options ​ Price Life (Years) ​ Intrinsic Value Options outstanding at December 31, 2019 7,192,357 3.42 7.2 ​ Options granted 2,539,403 2.80 ​ Options exercised (503,448) 1.21 ​ Options cancelled/forfeited (709,226) 6.20 ​ Options outstanding at December 31, 2020 8,519,086 3.13 7.3 ​ Options granted 2,581,647 2.63 ​ Options exercised (126,400) 0.60 ​ Options cancelled/forfeited (606,891) 6.61 ​ Options outstanding at December 31, 2021 10,367,442 2.83 7.1 ​ $ — Options exercisable at December 31, 2021 6,262,675 2.99 6.0 ​ $ — Vested and expected to vest at December 31, 2021 10,367,442 ​ $ — ​ Intrinsic value in the tables was calculated as the difference between the Company's stock price at December 31, 2021, of $0.49 per share, and the exercise price, multiplied by the number of options. Restricted Stock Units During the year ended December 31, 2020, the Company granted a total of 52,651 RSUs to executive officers of the Company. These RSUs vested on the one-year anniversary of the grant date. During the year ended December 31, 2020, the Company granted a total of 107,144 RSUs to directors of the Company. These RSUs vest ratably over one and three years . During the year ended December 31, 2021, the Company granted a total of 70,923 RSUs to certain employees of the Company. These RSUs vest on the one-year anniversary of the grant date. During the year ended December 31, 2021, the Company granted a total of 226,353 RSUs to directors of the Company. These RSUs vest ratably over one and three years . As of December 31, 2021, the unrecorded deferred stock-based compensation balance related to RSUs was approximately $250,000 and will be recognized over an estimated weighted-average amortization period of 1.0 years. The following table shows the Company's restricted stock unit activity during the years ended December 31, 2021, and 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average Aggregate ​ ​ Shares Grant Date Fair Value Intrinsic Value Restricted stock units outstanding at December 31, 2019 — ​ ​ Granted 159,795 2.81 ​ ​ ​ Restricted stock units outstanding at December 31, 2020 159,795 — ​ $ 458 Granted ​ 297,576 ​ 1.68 ​ ​ ​ Vested (124,081) 2.81 ​ ​ ​ Restricted stock units outstanding at December 31, 2021 333,290 1.80 ​ $ 163 ​ Performance Based Restricted Stock Awards In January 2018, the Company granted up to 365,000 shares of performance-based restricted stock units ("Performance Units") under the 2014 Plan primarily to executive officers, which were largely contingent upon the achievement of performance goals during the performance period beginning on the date of grant and ending on December 31, 2019 as set forth in each individual's Performance Unit agreement. Performance Units granted in January 2018 replaced Performance Units granted in April 2017 which expired. During 2018, 50,000 Performance Units were cancelled and as of December 31, 2018 315,000 Performance Units remained outstanding. The remaining 315,000 Performance Units expired in December 2019 as the performance goals were not achieved, and there are no Performance Units outstanding as of December 31, 2021.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	12 Months Ended
	Dec. 31, 2021
Accumulated Other Comprehensive Income Loss Net of Tax [Abstract]
Accumulated Other Comprehensive Income	12. Accumulated Other Comprehensive Income The change in accumulated other comprehensive income, which is reported as a component of stockholders’ equity, for the year ended December 31, 2021 is summarized below: ​ ​ ​ ​ ​ ​ ​ Unrealized ​ ​ Gain on ​ Marketable ​ ​ Securities Balance December 31, 2020 ​ $ 3 Other comprehensive income ​ ​ (3) Balance December 31, 2021 ​ $ — ​ ​

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Taxes
Income Taxes	13. Income Taxes In December 2017, in accordance with the SEC Staff Accounting Bulletin (“SAB”) 118–Income Tax Accounting Implications of the Tax Cuts and Jobs Act of 2017 (the “TCJA”), the Company recorded tax effects on a provisional basis based on a reasonable estimate. The TCJA did not have a material impact on the Company's financial statements because its deferred temporary differences are fully offset by a valuation allowance and the Company does not have any offshore earnings from which to record the mandatory transition tax. During 2018, the Company completed its analysis under SAB 118 and no additional tax effects due to rate-remeasurement were required to be recorded. On March 27, 2020 the US government enacted the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) which includes numerous modifications to income tax provisions, including a limitation on business interest expense and net operating loss provisions and the acceleration of alternative minimum tax credits. Given the Company’s history of losses, the CARES Act did not have a material impact on its tax provision. As of December 31, 2021, the Company had available net operating loss carryforwards (“NOLs”) of approximately $347.6 million for federal and $116.0 million for state income tax reporting purposes. Under the TCJA, the federal NOLs generated after 2017, approximately $154.0 million, can be carried forward indefinitely, while the NOLs generated through taxable years ending December 31, 2017, approximately $194.0 million, are available to offset future federal taxable income, if any, through 2038. The Company also has research and development tax credit carryforwards of approximately $6.4 million and $1.9 million for federal and state income tax reporting purposes, respectively, which are available to reduce federal income taxes, if any, through 2041 and state income taxes, if any, through 2036. The Internal Revenue Code of 1986, as amended (the “Code”) provides for a limitation on the annual use of NOLs and other tax attributes (such as research and development tax credit carryforwards) following certain ownership changes, as defined by the Code that could significantly limit the Company’s ability to utilize these carryforwards. At this time, the Company has not completed a study to assess whether an ownership change under Section 382 of the Code has occurred, or whether there have been multiple ownership changes since the Company’s formation, due to the costs and complexities associated with such a study. The Company is likely to have experienced various ownership changes, as defined by the Code, as a result of past financings. Accordingly, the Company’s ability to utilize the aforementioned carryforwards may be limited. Additionally, U.S. tax laws limit the time during which these carryforwards may be applied against future taxes. Therefore, the Company may not be able to take full advantage of these carryforwards for federal and state income tax purposes. The Company does not have any significant unrecognized tax benefits. As of December 31, 2021, the Company has not accrued interest or penalties related to uncertain tax positions. The Company’s tax returns for the years ended December 31, 2018 through December 31, 2020 are still subject to examination by major tax jurisdictions. However, the Internal Revenue Service (“IRS”) and state tax jurisdictions can audit the NOLs generated in prior years in the years that those NOLs are utilized. For all years through December 31, 2021, the Company generated research credits but has not conducted a study to document the qualified activities. This study may result in an adjustment to the Company’s research and development credit carryforwards; however, until a study is completed and any adjustment in known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company’s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance. The tax effects of temporary differences that give rise to significant portions of the deferred tax assets are presented below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Deferred tax assets: ​ ​ Net operating loss carryforwards ​ $ 81,102 ​ $ 66,907 Research credit carryforward ​ 7,943 ​ 7,909 Stock options and other ​ 2,114 ​ 1,962 Total gross deferred tax assets ​ 91,159 ​ 76,778 Valuation allowance for deferred tax assets ​ (91,159) ​ (76,778) Net deferred tax assets ​ $ — ​ $ — ​ The net change in the valuation allowance for the years ended December 31, 2021 and 2020 was an increase of $14.4 million and an increase of $10.6 million, respectively. A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 2019 Federal income tax at statutory rate 21.0 % 21.0 % 21.0 % State income tax benefit, net of federal benefit 0.3 % 1.0 % 7.0 % Research and development tax credits 0.2 % 0.7 % 4.0 % Other (2.2) % (2.0) % (4.0) % Increase to valuation allowance (19.3) % (20.7) % (28.0) % Effective income tax rate 0.0 % 0.0 % 0.0 % ​ Sale of New Jersey Net Operating Losses The Company has participated in the State of New Jersey’s Technology Business Tax Certificate Transfer Program (the “Program”) sponsored by The New Jersey Economic Development Authority. The Program enables approved biotechnology companies with unused NOLs and unused research and development credits to sell these tax benefits for at least 80% of the value of the tax benefits to unaffiliated, profitable corporate taxpayers in the State of New Jersey. The Program is administered by The New Jersey Economic Development Authority and the New Jersey Department of the Treasury’s Division of Taxation. The Company had previously reached the maximum lifetime benefit of $15.0 million under the historical Program, however in January 2021 the Program was amended to extend the maximum lifetime benefit to $20.0 million. The Company received final approval in March 2022 for approximately

2019 Retention Plan

2019 Retention Plan	12 Months Ended
	Dec. 31, 2021
2019 Retention Plan
2019 Retention Plan	14. 2019 Retention Plan ​ In July 2019, the Company adopted a retention plan (the “2019 Retention Plan”) for all employees (with the exception of the Chairman and Chief Executive Officer) in order to induce such employees to remain employed by the Company through at least the extended PDUFA goal date of February 14, 2020. ​ Each employee who participated in the 2019 Retention Plan and remained continuously employed by the Company through the approval of Twirla was to be paid a lump-sum cash payment in an amount determined for each eligible employee by the Compensation Committee at the time of the adoption of the 2019 Retention Plan. If an eligible employee terminated employment prior to the approval for any reason, no such retention payment was payable to the eligible employee. With the approval of Twirla in February 2020, the cash portion of the 2019 Retention Plan in the amount of approximately $0.3 million was expensed and paid to eligible employees in February 2020. ​ All employees (with the exception of the Chairman and Chief Executive Officer) who were employed by the Company as of July 3, 2019 were also granted a stock option to purchase the number of shares of common stock as approved by the Compensation Committee, with a per share exercise price of $1.48 , representing the closing price of the Company’s common stock as reported by Nasdaq on the date of grant. For each option, 50% of the option vested on July 3, 2020 and the remaining 50% vested on December 31, 2020. In addition, the vesting schedule for the stock options granted in January 2019 was amended for all employees (with the exception of the Chairman and Chief Executive Officer) holding such options who were employed on July 3, 2019 as follows: 50% of the option vested on January 29, 2020, 25% vested on June 30, 2020 and the remaining 25 % vested on December 31, 2020. The change in vesting schedule was approved by the Compensation Committee and did not have a material impact on the Company’s statement of operations.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies
Commitments and Contingencies	15. Commitments and Contingencies The Company has several firm purchase commitments, primarily related to the manufacture and supply of Twirla and the supply of a field force of sales representatives to provide certain detailing services, sales operation services, compliance services, and training services. Future firm purchase commitments under these agreements, the last of which ends in 2030, total $5.2 million. This amount does not represent all of the Company’s anticipated purchases in the future, but instead represents only purchases that are the subject of contractually obligated minimum purchases. The minimum commitments disclosed are determined based on non-cancelable minimum spend in 2021 or termination amounts. Additionally, the Company purchases products and services as needed with no firm commitment. The Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. An unfavorable outcome to any legal matter, if material, could have an adverse effect on the Company's operations or its financial position. As of December 31, 2021, the Company has not recorded a provision for any contingent losses.

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2021
Subsequent Event [Abstract]
Subsequent Event	16. Subsequent Events On January 7, 2022, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment, or the Certificate of Amendment, to the Company’s Amended and Restated Certificate of Incorporation, to increase the number of shares of common stock authorized for issuance from 150,000,000 shares to 300,000,000 shares. The Certificate of Amendment was effective upon filing, and was approved at a special meeting of stockholders (the “Special Meeting”) of the Company held on January 7, 2022. ​ On January 7, 2022, the Company and Perceptive entered into the Second Amendment (see Note 9). On January 7, 2022, the Company prepaid $5.0 million of the outstanding debt, and in accordance with the terms of the Second Amendment, no prepayment premium was due with the prepayment. ​ On March 10, 2022, the Company and Perceptive entered into a third amendment to the Perceptive Credit Agreement, as amended (the “Third Amendment”). The Third Amendment waived the Company’s obligations to (1) comply with certain financial covenants relating to minimum revenue requirements through September 30, 2022, conditioned upon the satisfaction of certain conditions, including the Company raising additional capital and prepaying a portion of its outstanding debt by April 30, 2022 and (2) file financial statements along with its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 that are not subject to any “going concern” qualification. ​ On March 13, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single healthcare-focused institutional investor (the “Purchaser”), pursuant to which the Company issued, in a registered direct offering (the “2022 Preferred Stock Offering”), 2,425 shares of Series A convertible preferred stock (the “Series A Preferred Stock”) and 2,425 shares of Series B convertible preferred stock (the “Series B Preferred Stock”) and Series A warrants (the “Series A Warrants”) to purchase up to an aggregate of 24,250,000 shares of the common stock of the Company (the “Common Stock”) and Series B warrants (the “Series B Warrants”) to purchase up to an aggregate of 24,250,000 shares of Common Stock. Each share of Series A Preferred Stock and Series B Preferred Stock has a stated value of $1,000 per share and a conversion price of $0.20 per share. The shares of preferred stock issued in the offering are convertible into an aggregate of 24,250,000 shares of Common Stock. The Series A Warrants have an exercise price of $0.26 per share, will become exercisable six months following the date of issuance, and will expire 5 years following the initial exercise date. The Series B Warrants have an exercise price of $0.26 per share, will become exercisable six months following the date of issuance, and will expire one and one-half years following the initial exercise date. The Purchase Agreement contains customary representations and warranties and agreements of the Company and the Purchaser and customary indemnification rights and obligations of the parties. Total gross proceeds from the 2022 Preferred Stock Offering, before deducting the placement agent's fees and other estimated offering expenses, are $4.9 million. The 2022 Preferred Stock Offering closed on March 14, 2022.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of revenue and expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, revenue recognition, costs of product revenues, the accounting for common stock warrants, stock-based compensation, and accounting for research and development costs. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. ​
Risks and Uncertainties	Risks and Uncertainties While Twirla has been approved by the FDA, other potential product candidates developed by the Company will require approval from the FDA prior to commercial sales. There can be no assurance that the Company’s other product candidates will receive the required approval. If the Company is denied approval or such approval is delayed, or is unable to obtain the necessary financing to complete development and approval, there could be a material adverse impact on the Company’s financial condition and results of operations. ​ It should be noted that current public health threats could adversely affect the Company’s ongoing or planned business operations. In particular, the ongoing COVID-19 pandemic has resulted in federal, state and local governments and private entities mandating various restrictions, including travel restrictions, access restrictions, restrictions on public gatherings, and stay at home orders. The effect of these orders, government imposed quarantines and measures the Company has taken, such as implementing work-at-home policies, may negatively impact productivity, disrupt the Company’s business and could delay the Company’s commercialization timeline. The Company cannot presently predict the scope and severity of any potential business shutdowns or disruptions, but if the Company or any of the third parties with whom it engages, including personnel at third-party manufacturing facilities and other third parties with whom the Company conducts business, were to experience shutdowns or other business disruptions, the Company’s ability to conduct its business in the manner and on the timeline presently planned could be materially and adversely impacted. It is unknown how long these conditions will last and what the complete effect will be on the Company. While to date we have been able to continue to execute our overall business plan, some of our business activities have been slowed and taken longer to complete and we continue to adjust to the challenges of operating in a largely remote setting with our employees. We have only recently launched our commercial activities for Twirla and begun engaging with healthcare providers to promote Twirla. We expect that, as we broaden our sales detailing activities, in some instances our sales force may encounter challenges engaging with healthcare providers during this on-going pandemic. Although many areas of the United States have begun to re-open access to offices and other commercial facilities, there continue to be areas where restrictions remain in place, which may have the potential to affect our ability to conduct our business. Further, new variants, including those which are more easily transmissible or resistant to existing vaccines, may lead to new shutdowns or business disruptions in the future. The Company will continue to closely monitor events as they develop and evaluate alternative, mitigating measures it can implement if needed.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly-liquid investments with an original maturity of three months or less when purchased to be cash equivalents. All cash and cash equivalents are held in United States financial institutions. Cash and cash equivalents include money market funds that invest primarily in commercial paper and U.S. government and U.S. government agency obligations. The Company maintains balances with financial institutions in excess of the Federal Deposit Insurance Corporation limit.
Marketable Securities	Marketable Securities The Company invests a portion of its excess cash balances in marketable securities, including U.S. government agency securities, and highly rated corporate bonds. The Company classifies all of its marketable securities as current assets on the balance sheet because they are available-for-sale and available to fund current operations. Marketable securities are stated at fair value with unrealized gains and losses included as a component of accumulated other comprehensive income (loss), which is a separate component of stockholders' equity, until such gains and losses are realized. If a decline in the fair value is considered other-than-temporary, based on available evidence, the unrealized loss is reclassified from accumulated other comprehensive income (loss) to the statements of operations. Realized gains and losses are determined on the specific identification method and are included in other income.
Trade Accounts Receivable and Allowances	Trade Accounts Receivable and Allowances Trade accounts receivable are amounts owed to the Company by its customers for product that has been delivered. The trade accounts receivable are recorded at the invoice amount, less prompt pay and other discounts, chargebacks, and an allowance for credit losses, if any. The allowance for credit losses is the Company’s estimate of losses over the life of the receivables. The Company evaluates forward looking economic factors and uses professional judgment to determine the allowance for credit losses. The credit loss reserves are reviewed and adjusted periodically. Credit loss reserves were not material as of December 31, 2021 and 2020, respectively. ​ Trade accounts receivable are aged based on the contractual payment terms. When the collectability of an invoice is no longer probable, the Company will create a reserve for that specific receivable. If a receivable is determined to be uncollectible, it is charged against the general credit loss reserve or the reserve for the specific receivable, if one exists.
Fair Value of Financial Instruments	Fair Value of Financial Instruments In accordance with Accounting Standards Codification (“ASC”) 825, Financial Instruments Other financial instruments, including accounts receivable, accounts payable and accrued liabilities, are carried at cost, which approximates fair value given their short-term nature.
Inventory	Inventory Inventory is valued utilizing the weighted average costing method. The Company records an inventory reserve for losses associated with dated, expired, excess or obsolete items. This reserve is based on management’s current knowledge with respect to inventory levels, planned production and sales volume assumptions. During the year ended December 31, 2021, the Company established a reserve of approximately $5.3 million for inventory not expected to be sold prior to its shelf life date. ​ The Company’s third-party manufacturer, Corium, completed the validation of the commercial manufacturing process for Twirla in the fourth quarter of 2020. The costs associated with validation batches were expensed as research and development expenses during the period the costs were incurred. The Company used this validation product for commercial supplies and samples of Twirla into May 2021. Since the Company did not capitalize any validation product, all sales of this validation product had no associated product cost. During the year ended Dectember 31, 2021, units sold with no associated product cost were approximately 3,000 . Had such inventory been valued at acquisition cost, it would have resulted in an immaterial increase to cost of goods sold and a corresponding decrease to gross profit.
Property and Equipment	Property and Equipment Property and equipment, consisting of office equipment, computer equipment and manufacturing equipment, is stated at cost, less accumulated depreciation. Depreciation is computed using the straight- line method over the estimated useful lives of the assets. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to earnings in the period in which costs are incurred. Improvements and additions are capitalized in accordance with Company policy. ​
Long-Lived Assets	Long-Lived Assets In accordance with ASC 360, Property, Plant and Equipment ​
Research and Development Expense	Research and Development Expense Research and development costs are expensed as incurred. Research and development expense consists primarily of costs related to personnel, including salaries and other personnel-related expenses, expenses related to manufacturing, clinical trial expenses, consulting fees and support services used in drug development. All research and development costs are charged to operations as incurred in accordance with ASC 730, Research and Development In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are deferred and are expensed when the activity has been performed or when the goods have been received. ​
Advertising Costs	Advertising Costs The Company has elected to expense advertising costs when incurred. Advertising costs totaled
Deferred Financing Costs	Deferred Financing Costs Costs directly attributable to the Company’s term loan (see Note 9) are deferred and reported as a reduction of the related term loan. These costs represent legal fees and other costs related to the term loan and are being amortized utilizing the straight-line method over the term of the loan. Amortization of deferred financing costs charged to interest expense was approximately $277,000, $231,000 and $0 for the years ended December 31, 2021, 2020 and 2019, respectively. ​
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments which potentially subject the Company to credit risk consist principally of cash, cash equivalents and marketable securities. The Company invests its cash, cash equivalents and marketable securities in debt instruments and interest-bearing accounts in United States financial institutions, the balances of which exceed federally insured limits. The Company has not Major customers of the Company are defined as those constituting greater than 10% of its total revenue. In 2021, the Company had sales to customers that individually accounted for more than 10% of our total revenue. These customers had sales of of total revenues in the aggregate. Accounts receivable related to each of these major customers comprised
Revenue Recognition	Revenue Recognition The Company recognizes revenue from the sale of its product, Twirla, in accordance with ASC 606, Revenue from Contracts with Customers ​ In accordance with ASC 606, the Company recognizes revenue at the point in time when its performance obligation is satisfied by transferring control of the promised goods or services to a customer. In accordance with the Company’s contracts with customers, control of the product is transferred upon the conveyance of title, which occurs when the product is sold to and received by a customer. The Company’s customers are located in the United States and consist primarily of wholesale distributors. Trade accounts receivable due to the Company from contracts with its customers are stated separately in the balance sheet, net of various allowances as described in the Trade Accounts Receivable and Allowance policy. ​ The amount of revenue recognized by the Company is equal to the amount of consideration that is expected to be received from the sale of product to its customers. Revenue is only recognized when it is probable that a significant reversal will not occur in future periods. To determine whether a significant reversal will occur in future periods, the Company assesses both the likelihood and magnitude of any such potential reversal of revenue. ​ Twirla is sold to customers at the wholesale acquisition cost (WAC). However, the Company records product revenue, net of reserves for applicable variable consideration. These types of variable consideration items reduce revenue and include the following: ​ •Distribution services fees •Prompt pay and other discounts •Product returns •Chargebacks •Rebates •Co-payment assistance ​ An estimate for each variable consideration item is made and is recorded in conjunction with the revenue being recognized. Generally, if the estimated amount is payable to a customer, it is recorded as a reduction to accounts receivable. If the estimated amount is payable to an entity other than a customer, it is recorded as a current liability. An estimated amount of variable consideration may differ from the actual amount. At each balance sheet date, these provisions are analyzed, and adjustments are made if necessary. Any adjustments made to these provisions would affect net product revenue and earnings in the current period. ​ In accordance with ASC 606, the Company must make significant judgments to determine the estimate for certain variable consideration. For example, the Company must estimate the percentage of end-users that will obtain the product through public insurance such as Medicaid or through private commercial insurance. To determine these estimates, the Company relied on industry standard data and trend analysis since historical sales data was not available as Twirla was launched in December 2020. As historical data becomes available, the Company will incorporate that data into its estimates of variable consideration. ​ The specific considerations that the Company uses in estimating these amounts related to variable considerations are as follows. ​ Distribution services fees – The Company pays distribution service fees to its wholesale distributors. These fees are a contractually fixed percentage of WAC and are calculated at the time of sale based on the purchase amount. The Company records these fees as contra trade accounts receivable on the balance sheet. ​ Prompt pay and other discount ​ The Company may also give other discounts to its customers to incentivize purchases and promote customer loyalty. The terms of such discounts may vary by customer. These discounts reduce gross product revenue at the time the revenue is recorded. ​ Product returns ​ Chargebacks ​ Rebates ​ Co-payment assistance ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ Allowances for ​ Payments & ​ December 31, ​ 2020 current period sales credits 2021 Customer credits, discounts and allowances ​ $ 187 ​ $ 825 ​ $ (641) ​ $ 371 Rebates and co-pay assistance ​ ​ 116 ​ ​ 1,055 ​ ​ (502) ​ ​ 669 Total ​ $ 303 ​ $ 1,880 ​ $ (1,143) ​ $ 1,040 ​
Warrants	Warrants The Company accounts for its warrants to purchase common stock in accordance with ASC 480, Distinguishing Liabilities from Equity . On January 1, 2019, the Company adopted the provisions of Accounting Standards Update (“ASU”) 2017-11 Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception, In connection with entering into a senior secured term loan facility in February 2020, the Company issued warrants to purchase 1,400,000 shares of its common stock. In connection with an amendment to that facility in February 2021, the Company issued a warrant to purchase 450,000 shares of the Company’s common stock. In connection with an underwritten public offering completed in October 2021, the Company issued warrants to purchase 13,333,324 shares of its common stock. This offering also triggered an adjustment to the exercise price of the existing warrants mentioned above, which resulted in a reduction of the strike price for these warrants. This reduction resulted in an immaterial increase to additional paid in capital. S
Income Taxes	Income Taxes The Company accounts for deferred taxes using the asset and liability method as specified by ASC 740, Income Taxes The Company has adopted the authoritative guidance on accounting for and disclosure of uncertainty in tax positions which prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. The Company has no ​
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC 718, Compensation-Stock Compensation . The Company grants stock options for a fixed number of shares to employees and non-employees with an exercise price equal to the fair value of the shares at grant date. Compensation cost is recognized for all share-based payments granted and is based on the grant-date fair value estimated using the weighted-average assumption of the Black-Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. The Company elects to account for forfeitures when they occur. The equity instrument is not considered to be issued until the instrument vests. As a result, compensation cost is recognized over the requisite service period with an offsetting credit to additional paid-in capital. The Company also awards restricted stock units (“RSUs”) to employees and its board of directors. RSUs are generally subject to forfeiture if employment terminates prior to the completion of the vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. Cost associated with performance-based restricted stock units with a performance condition which affects the vesting is recognized only if the performance condition is probable of being satisfied. ​
Segment Information	Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception. ​
Net Loss Per Share	Net Loss Per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, common stock warrants, unvested RSUs and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented. The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share for the years ended December 31, 2021, 2020 and 2019, respectively, because to do so would be anti-dilutive (in common equivalent shares): ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 2019 Common stock warrants ​ 15,183,324 1,400,000 180,274 Unvested restricted stock units ​ 333,290 159,795 — Common stock options ​ 10,367,442 8,519,086 7,192,357 Total ​ 25,884,056 10,078,881 7,372,631
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures. In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part 1) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. additional paid-in capital. As a result of the adoption of ASU 2017-11, effective January 1, 2019, the Company no longer measures these warrants at fair value. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. ASU 2016-13 was adopted by the Company on January 1, 2020 and had no current impact on the Company as the Company did not have any financial instruments covered by the topic on the date of adoption. In December 2020, the Company recognized its first sales of Twirla resulting in a receivable of $0.9 million at December 31, 2020 and an immaterial allowance for credit losses. As of December 31, 2021, receivables total $1.5 million, and the allowance for credit losses is immaterial. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). This guidance simplifies the accounting for income taxes by, among other things, reducing complexity in the interim-period accounting for year-to-date loss limitations and changes in tax laws. The guidance is effective for the Company on January 1, 2021. The Company is currently evaluating the impact of adopting this standard and does not expect the guidance to have a material impact on its consolidated financial statements. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848), an expansion of ASU 2020-04: Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2021-01”). This guidance permits entities to elect certain optional expedients and exceptions when accounting for derivative contracts and certain hedging relationships affected by changes in the interest rates used for discounting cash flows, for computing variation margin settlements, and for calculating price alignment interest) in connection with reference rate reform activities under way in global financial markets (the “discounting transition”). The guidance was effective immediately and did not have an impact on our consolidated financial statements. ​ Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Significant Accounting Policies
Summary of sales allowances and related accruals	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ Allowances for ​ Payments & ​ December 31, ​ 2020 current period sales credits 2021 Customer credits, discounts and allowances ​ $ 187 ​ $ 825 ​ $ (641) ​ $ 371 Rebates and co-pay assistance ​ ​ 116 ​ ​ 1,055 ​ ​ (502) ​ ​ 669 Total ​ $ 303 ​ $ 1,880 ​ $ (1,143) ​ $ 1,040
Schedule of outstanding potentially dilutive securities excluded from calculation of diluted net loss per share	The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share for the years ended December 31, 2021, 2020 and 2019, respectively, because to do so would be anti-dilutive (in common equivalent shares): ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 2019 Common stock warrants ​ 15,183,324 1,400,000 180,274 Unvested restricted stock units ​ 333,290 159,795 — Common stock options ​ 10,367,442 8,519,086 7,192,357 Total ​ 25,884,056 10,078,881 7,372,631

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Measurements
Schedule of financial instruments measured at fair value by level within the fair value hierarchy	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1 Level 2 Level 3 December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 19,143 ​ $ — ​ $ — Total assets at fair value ​ $ 19,143 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1 Level 2 Level 3 December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 14,463 ​ $ — ​ $ — Marketable securities ​ ​ — ​ ​ 40,008 ​ ​ — Total assets at fair value ​ $ 14,463 ​ $ 40,008 ​ $ —

Marketable Securities (Tables)

Marketable Securities (Tables)	12 Months Ended
	Dec. 31, 2021
Marketable Securities
Summary of marketable securities, classified as available-for-sale	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross Unrealized ​ ​ ​ ​ Amortized ​ ​ ​ ​ ​ ​ ​ Fair ​ Cost ​ Gains ​ Losses ​ ​ Value December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ U.S. government obligations (maturing in one year or less) $ 7,035 ​ $ 2 ​ $ — ​ $ 7,037 Corporate debt securities (maturing in one year or less) 32,970 ​ 1 ​ ​ — ​ 32,971 Total marketable securities $ 40,005 ​ $ 3 ​ $ — ​ $ 40,008

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Prepaid Expenses
Schedule of prepaid expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Prepaid insurance ​ $ 775 ​ $ 680 Other ​ 1,508 ​ 769 Total prepaid expenses and other current assets ​ $ 2,283 ​ $ 1,449

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Property and Equipment
Schedule of components of property and equipment	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ Estimated ​ 2021 2020 Life Office equipment ​ $ 7 ​ $ — 5 years Computer equipment ​ 113 ​ — 3 Years Manufacturing equipment ​ 14,477 ​ 14,328 7 years ​ ​ 14,597 ​ 14,328 ​ ​ Less: accumulated depreciation ​ (2,150) ​ (85) Property and equipment ​ $ 12,447 ​ $ 14,243

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Accrued Liabilities
Schedule of accrued liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Accrued compensation ​ $ 2,086 ​ $ 1,697 Accrued professional fees and other ​ 1,477 ​ 1,651 Total accrued liabilities ​ $ 3,563 ​ $ 3,348

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases
Maturity of lease liabilities	Future minimum lease payments under non-cancellable leases as of December 31, 2021 were as follows: ​ ​ ​ ​ ​ ​ Year ending December 31, ​ ​ ​ 2022 ​ ​ 277 2023 ​ ​ 390 2024 ​ ​ 398 2025 $ 101 Total ​ $ 1,166 Less: Interest ​ (207) Present value of lease liability ​ $ 959

Credit Agreement and Guaranty (

Credit Agreement and Guaranty (Tables)	12 Months Ended
	Dec. 31, 2021
Credit Agreement and Guaranty
Schedule of carrying amount of term loan	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ ​ 2021 ​ 2020 Notes payable $ 20,000 ​ $ 20,000 Debt issuance costs ​ ​ (550) ​ ​ (828) Warrant discount ​ ​ (2,617) ​ ​ (2,791) Total debt ​ $ 16,833 ​ $ 16,381 Less, current portion ​ ​ 16,833 ​ ​ — Long-term debt, less current portion ​ $ — ​ $ 16,381

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	12 Months Ended
	Dec. 31, 2021
Equity Incentive Plans
Schedule of stock-based compensation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, ​ 2021 2020 2019 Cost of goods sold ​ $ 271 ​ $ 14 ​ $ — Research and development ​ ​ 490 ​ ​ 651 ​ ​ 522 Selling and marketing ​ ​ 148 ​ ​ 108 ​ ​ — General and administrative ​ 2,429 ​ 2,045 ​ 1,240 Total ​ $ 3,338 ​ $ 2,818 ​ $ 1,762
Schedule of assumptions used to compute employee stock-based compensation	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2021 2020 2019 Risk‑free interest rate .66% - 1.51 % .40% - 1.68 % 1.74% ‑ 2.61 % Expective volatility 105% ‑ 106 % 65% ‑ 106 % 65 % Expected dividend yield 0 % 0 % 0 % Expected life (in years) 6.25 6.25 6.25 ​
Summary of options outstanding, vested and exercisable	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ Average Remaining ​ ​ ​ ​ ​ ​ Exercise Contractual ​ Aggregate ​ ​ Options ​ Price Life (Years) ​ Intrinsic Value Options outstanding at December 31, 2019 7,192,357 3.42 7.2 ​ Options granted 2,539,403 2.80 ​ Options exercised (503,448) 1.21 ​ Options cancelled/forfeited (709,226) 6.20 ​ Options outstanding at December 31, 2020 8,519,086 3.13 7.3 ​ Options granted 2,581,647 2.63 ​ Options exercised (126,400) 0.60 ​ Options cancelled/forfeited (606,891) 6.61 ​ Options outstanding at December 31, 2021 10,367,442 2.83 7.1 ​ $ — Options exercisable at December 31, 2021 6,262,675 2.99 6.0 ​ $ — Vested and expected to vest at December 31, 2021 10,367,442 ​ $ —
Schedule of restricted stock activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average Aggregate ​ ​ Shares Grant Date Fair Value Intrinsic Value Restricted stock units outstanding at December 31, 2019 — ​ ​ Granted 159,795 2.81 ​ ​ ​ Restricted stock units outstanding at December 31, 2020 159,795 — ​ $ 458 Granted ​ 297,576 ​ 1.68 ​ ​ ​ Vested (124,081) 2.81 ​ ​ ​ Restricted stock units outstanding at December 31, 2021 333,290 1.80 ​ $ 163

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Tables)	12 Months Ended
	Dec. 31, 2021
Accumulated Other Comprehensive Income Loss Net of Tax [Abstract]
Schedule of change in accumulated other comprehensive income, which is reported as a component of stockholders' equity	​ ​ ​ ​ ​ ​ ​ Unrealized ​ ​ Gain on ​ Marketable ​ ​ Securities Balance December 31, 2020 ​ $ 3 Other comprehensive income ​ ​ (3) Balance December 31, 2021 ​ $ —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Taxes
Schedule of tax effects of temporary differences that give rise to significant portions of deferred tax assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Deferred tax assets: ​ ​ Net operating loss carryforwards ​ $ 81,102 ​ $ 66,907 Research credit carryforward ​ 7,943 ​ 7,909 Stock options and other ​ 2,114 ​ 1,962 Total gross deferred tax assets ​ 91,159 ​ 76,778 Valuation allowance for deferred tax assets ​ (91,159) ​ (76,778) Net deferred tax assets ​ $ — ​ $ —
Schedule of reconciliation of U.S. statutory income tax rate to effective tax rate	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 2019 Federal income tax at statutory rate 21.0 % 21.0 % 21.0 % State income tax benefit, net of federal benefit 0.3 % 1.0 % 7.0 % Research and development tax credits 0.2 % 0.7 % 4.0 % Other (2.2) % (2.0) % (4.0) % Increase to valuation allowance (19.3) % (20.7) % (28.0) % Effective income tax rate 0.0 % 0.0 % 0.0 %

Organization and Description _2

Organization and Description of Business (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Nature of Operations
Accumulated deficit	$ 387,117	$ 312,223
Cash, cash equivalents and marketable securities	$ 19,100

Organization and Description _3

Organization and Description of Busines - Basis of Presentation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Organization and Description of Business
Selling and marketing	$ 43,444	$ 23,285	$ 1,085

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Inventory (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)item
Summary of Significant Accounting Policies
Inventory reserve | $	$ 5.3
Number of units sold | item	3,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Advertising Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Advertising costs	$ 13.8	$ 5.5
Manufacturing equipment
Estimated useful life (in years)	7 years	7 years	7 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Deferred Financing Costs (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Interest expense [Member]
Deferred Financing Costs
Amortization of deferred financing costs	$ 277,000	$ 231,000	$ 0

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)customer	Dec. 31, 2020USD ($)
Concentration of risk, financial assets
Financial instruments with off-balance sheet risk of accounting loss, assets	$ 0
Concentration risk, financial liabilities
Financial instruments with off-balance sheet risk of accounting loss, liabilities	0
Total revenue	$ 4,101	$ 749
Customer Concentration Risk
Concentration risk, financial liabilities
Number of major customers | customer	3
Customer Concentration Risk | Sales Revenue | Customer One
Concentration risk, financial liabilities
Total revenue	$ 1,300
Customer Concentration Risk | Sales Revenue | Customer Two
Concentration risk, financial liabilities
Total revenue	1,300
Customer Concentration Risk | Sales Revenue | Customer Three
Concentration risk, financial liabilities
Total revenue	$ 1,200
Customer Concentration Risk | Sales Revenue | Three Customers
Concentration risk, financial liabilities
Concentration risk, percentage	93.00%
Customer Concentration Risk | Accounts Receivable | Customer One
Concentration risk, financial liabilities
Concentration risk, percentage	35.00%
Customer Concentration Risk | Accounts Receivable | Customer Two
Concentration risk, financial liabilities
Concentration risk, percentage	34.00%
Customer Concentration Risk | Accounts Receivable | Customer Three
Concentration risk, financial liabilities
Concentration risk, percentage	29.00%

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Co-Payment Assistance (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Accounts Receivable, Beginning Balance	$ 303
Allowances for current period sales	1,880
Payments & credits	(1,143)
Accounts Receivable, Ending Balance	1,040
Customer credits, discounts And allowances
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Accounts Receivable, Beginning Balance	187
Allowances for current period sales	825
Payments & credits	(641)
Accounts Receivable, Ending Balance	371
Rebates and co-pay assistance
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Accounts Receivable, Beginning Balance	116
Allowances for current period sales	1,055
Payments & credits	(502)
Accounts Receivable, Ending Balance	$ 669

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Warrants (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Oct. 31, 2021	Feb. 28, 2021	Dec. 31, 2020	Feb. 29, 2020	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Warrants
Cumulative effect adjustment	$ 9,271			$ 49,328		$ 45,745		$ 20,174
Common stock that can be purchased with warrants (in shares)		13,333,324	450,000
Common stock warrants
Warrants
Common stock that can be purchased with warrants (in shares)					1,400,000
Accumulated Deficit
Warrants
Cumulative effect adjustment	$ (387,117)			$ (312,223)		(260,370)		$ (241,551)
Cumulative Effect, Period of Adoption, Adjusted Balance [Member] | Accumulated Deficit
Warrants
Cumulative effect adjustment						$ (213)
Cumulative Effect, Period of Adoption, Adjustment [Member] | ASU 2017-11 | Accumulated Deficit
Warrants
Cumulative effect adjustment							$ 213

Summary of Significant Accou_10

Summary of Significant Accounting Policies - Income Taxes (Details) $ in Thousands	Dec. 31, 2021USD ($)
Uncertainty in tax positions
Uncertain tax positions	$ 0

Summary of Significant Accou_11

Summary of Significant Accounting Policies - Net Loss Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Anti-dilutive securities
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)	25,884,056	10,078,881	7,372,631
Common stock warrants
Anti-dilutive securities
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)	15,183,324	1,400,000	180,274
Restricted Stock Units
Anti-dilutive securities
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)	333,290	159,795
Common stock options
Anti-dilutive securities
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)	10,367,442	8,519,086	7,192,357

Summary of Significant Accou_12

Summary of Significant Accounting Policies - Segment Information (Details)	12 Months Ended
	Dec. 31, 2021segment
Segment Information
Number of operating segments	1
Number of reporting segments	1

Summary of Significant Accou_13

Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Recent Accounting Pronouncements
Cumulative effect adjustment	$ 9,271	$ 49,328	$ 45,745		$ 20,174
Accounts receivable, net	1,533	865
Twirla
Recent Accounting Pronouncements
Accounts receivable, net	1,500	900
Additional Paid in Capital.
Recent Accounting Pronouncements
Cumulative effect adjustment	$ 396,376	$ 361,539	306,108		$ 261,722
Additional Paid in Capital. | Cumulative Effect, Period of Adoption, Adjusted Balance [Member]
Recent Accounting Pronouncements
Cumulative effect adjustment			$ 213
Additional Paid in Capital. | Cumulative Effect, Period of Adoption, Adjustment [Member] | ASU 2017-11
Recent Accounting Pronouncements
Cumulative effect adjustment				$ 213

Fair Value Measurements - Finan

Fair Value Measurements - Financial Instruments Measured at Fair Value by Hierarchy Level (Details) - Recurring - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Level 1
Assets:
Cash and cash equivalents	$ 19,143	$ 14,463
Total assets at fair value	$ 19,143	14,463
Level 2
Assets:
Marketable securities		40,008
Total assets at fair value		$ 40,008

Fair Value Measurements - Trans

Fair Value Measurements - Transfers Between Levels (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair value measurements
Asset transfers out of Level 1 into Level 2	$ 0	$ 0
Asset transfers out of Level 2 into Level 1	0	0
Asset transfers into (out of) Level 3	0	0
Liability transfers out of Level 1 into Level 2	0	0
Liability transfers out of Level 2 into Level 1	0	0
Liability transfers into (out of) Level 3	$ 0	$ 0

Marketable Securities (Details)

Marketable Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Marketable Securities [Line Items]
Amortized Cost (maturing in one year or less)	$ 40,005
Gross Unrealized Gain (maturing in one year or less)	3
Fair Value (maturing in one year or less)	$ 40,008
Investment-grade marketable securities in a continuous unrealized loss position for more than twelve months	0
Marketable securities	$ 0	$ 40,008
U.S. government obligations
Marketable Securities [Line Items]
Amortized Cost (maturing in one year or less)	7,035
Gross Unrealized Gain (maturing in one year or less)	2
Fair Value (maturing in one year or less)	7,037
Corporate debt securities
Marketable Securities [Line Items]
Amortized Cost (maturing in one year or less)	32,970
Gross Unrealized Gain (maturing in one year or less)	1
Fair Value (maturing in one year or less)	$ 32,971

Prepaid Expenses (Details)

Prepaid Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Prepaid Expenses
Prepaid insurance	$ 775	$ 680
Other	1,508	769
Total prepaid expenses and other current assets	$ 2,283	$ 1,449

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Property and Equipment
Property and equipment, gross	$ 14,597	$ 14,328
Less: accumulated depreciation	(2,150)	(85)
Property and equipment, net	12,447	$ 14,243
Office equipment
Property and Equipment
Property and equipment, gross	$ 7
Estimated Life (in years)	5 years	5 years
Computer equipment
Property and Equipment
Property and equipment, gross	$ 113
Estimated Life (in years)	3 years	3 years
Manufacturing equipment
Property and Equipment
Property and equipment, gross	$ 14,477	$ 14,328
Estimated Life (in years)	7 years	7 years	7 years

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accrued Liabilities
Accrued compensation	$ 2,086	$ 1,697
Accrued professional fees and other	1,477	1,651
Total accrued liabilities	$ 3,563	$ 3,348

Leases - Summary (Details)

Leases - Summary (Details)	12 Months Ended
	Dec. 31, 2021USD ($)lease	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Leases
Number of finance leases | lease	0
Number of operating leases | lease	1
Lease liability	$ 959,000
Lease assets	949,000	$ 138,000
Operating lease expense	180,000,000	190,000,000
Operating lease expense information:
Cash paid for amounts included in measurement of lease liabilities	131,000	$ 184,000	$ 152,000
ROU assets obtained in exchange for lease liabilities	$ 969,000
Weighted-average remaining lease term (years)	3 years 3 months
Weighted-average discount rate	11.80%

Leases - Maturity of lease liab

Leases - Maturity of lease liabilities (Details) $ in Thousands	Dec. 31, 2021USD ($)
Operating Leases
2022	$ 277
2023	390
2024	398
2025	101
Total	1,166
Less: Interest	(207)
Present value of lease liability	$ 959

Credit Agreement and Guaranty_2

Credit Agreement and Guaranty (Details)	Jan. 07, 2022USD ($)	Feb. 26, 2021USD ($)	Feb. 10, 2020USD ($)item$ / sharesshares	Dec. 31, 2023USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Oct. 31, 2021$ / sharesshares	Sep. 30, 2021$ / shares	Feb. 28, 2021shares	Feb. 10, 2021$ / sharesshares
Debt Instrument [Line Items]
Amount borrowed						$ 20,000,000
Interest rate (as a percent)			11.75%			11.75%
Percentage of annual interest rate			3.00%
Common stock that can be purchased with warrants (in shares) | shares							13,333,324		450,000
Proceeds from warrant exercises			$ 20,000,000
Fair value of warrants			$ 3,600,000
Perceptive Credit Agreement
Debt Instrument [Line Items]
Percentage of outstanding debt			1.50%
Minimum cash covenants			$ 3,000,000
Revenue generated under debt				$ 87,100,000	$ 53,000,000
Perceptive Credit Agreement | Perceptive Warrants
Debt Instrument [Line Items]
Exercise price of warrants (in dollars per share) | $ / shares										$ 2.87
Common stock that can be purchased with warrants (in shares) | shares			1,400,000				1,850,000
Beneficial ownership percentage			19.99%
Facility fee percentage			1.00%
Perceptive Credit Agreement | First Seven Lakhs Shares
Debt Instrument [Line Items]
Exercise price of warrants (in dollars per share) | $ / shares			$ 3.74				$ 3.83	$ 4.67
Common stock that can be purchased with warrants (in shares) | shares			700,000				700,000
Perceptive Credit Agreement | Remaining Seven Lakhs Shares
Debt Instrument [Line Items]
Exercise price of warrants (in dollars per share) | $ / shares			$ 4.67				$ 3.11	3.74
Common stock that can be purchased with warrants (in shares) | shares			700,000				700,000
Perceptive Credit Agreement | Warrants
Debt Instrument [Line Items]
Exercise price of warrants (in dollars per share) | $ / shares							$ 2.43	$ 2.87
Common stock that can be purchased with warrants (in shares) | shares							450,000
Perceptive Credit Agreement, Tranche Four | Perceptive Warrants
Debt Instrument [Line Items]
Common stock that can be purchased with warrants (in shares) | shares										450,000
Senior secured delayed draw term loan facility | Perceptive Credit Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 35,000,000
Senior secured delayed draw term loan facility | Perceptive Credit Agreement, Tranche One
Debt Instrument [Line Items]
Amount borrowed			5,000,000
Senior secured delayed draw term loan facility | Perceptive Credit Agreement, Tranche Two
Debt Instrument [Line Items]
Amount borrowed			15,000,000
Senior secured delayed draw term loan facility | Perceptive Credit Agreement, Tranche Three
Debt Instrument [Line Items]
Amount borrowed			$ 15,000,000
Senior secured delayed draw term loan facility | Perceptive Credit Agreement, Tranche Four
Debt Instrument [Line Items]
Amount borrowed		$ 10,000,000
Subsequent event | Perceptive Credit Agreement
Debt Instrument [Line Items]
Repayments of Debt	$ 5,000,000
Debt Instrument, Prepayment Premium Due	$ 0
LIBOR | Perceptive Credit Agreement
Debt Instrument [Line Items]
Variable interest rate margin (as a percent)			10.25%
Interest rate for the base rate			1.50%
Prepayment Occur on or Before February, 10, 2022 | Perceptive Credit Agreement
Debt Instrument [Line Items]
Prepayment fee percent			8.00%
Prepayment Occur on or Before February, 10, 2023 | Perceptive Credit Agreement
Debt Instrument [Line Items]
Prepayment fee percent			4.00%
Prepayment Occur on or Before February, 10, 2024 | Perceptive Credit Agreement
Debt Instrument [Line Items]
Prepayment fee percent			2.00%
Option pricing model | Common stock warrants | Perceptive Warrants
Debt Instrument [Line Items]
Warrants and rights outstanding, term			7 years
Option pricing model | Common stock warrants | Perceptive Warrants | Volatility
Debt Instrument [Line Items]
Warrants, Measurement Input			0.700
Option pricing model | Common stock warrants | Perceptive Warrants | Risk free interest rate
Debt Instrument [Line Items]
Warrants, Measurement Input			0.0147
Option pricing model | Common stock warrants | Perceptive Warrants | Share price [Member]
Debt Instrument [Line Items]
Warrants, Measurement Input | item			4.01
Option pricing model | Common stock warrants | Maximum | Perceptive Warrants | Strike price
Debt Instrument [Line Items]
Warrants, Measurement Input | item			4.67
Option pricing model | Common stock warrants | Minimum | Perceptive Warrants | Strike price
Debt Instrument [Line Items]
Warrants, Measurement Input | item			3.74

Credit Agreement and Guaranty -

Credit Agreement and Guaranty - Carrying Amount Of term Loan (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Credit Agreement and Guaranty
Notes payable	$ 20,000	$ 20,000
Debt issuance costs	(550)	(828)
Warrant discount	(2,617)	(2,791)
Total	16,833	16,381
Less, current portion	$ 16,833
Current portion, long-term debt		$ 16,381

Stockholders' Equity - Amended

Stockholders' Equity - Amended and Restated Certificate of Incorporation (Details)	12 Months Ended
	Dec. 31, 2021classshares	Dec. 31, 2020shares
Stockholders' Equity
Common stock, authorized (in shares) | shares	150,000,000	150,000,000
Preferred stock, authorized (in shares) | shares	10,000,000
Board of Directors, number of classes | class	3
Term of Board member	3 years
Number of classes elected at each annual meeting | class	1
Minimum
Stockholders' Equity
Affirmative vote of all then-outstanding shares of capital stock for removal of directors (as a percent)	75.00%

Stockholders' Equity - Common S

Stockholders' Equity - Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 14, 2022	Oct. 08, 2021	Feb. 21, 2020	Aug. 31, 2019	Mar. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jan. 10, 2022	Oct. 31, 2021	Sep. 30, 2021	Mar. 18, 2021	Feb. 28, 2021	Feb. 10, 2021	Oct. 02, 2020	Feb. 10, 2020	Nov. 08, 2019	Jan. 23, 2019
Sale of stock
Common stock that can be purchased with warrants (in shares)										13,333,324			450,000
Proceeds from issuance of common stock in private placement, net of offering costs								$ 7,810
Number of warrants outstanding (in shares)										13,333,324			450,000
Perceptive Warrants | Perceptive Credit Agreement
Sale of stock
Common stock that can be purchased with warrants (in shares)										1,850,000						1,400,000
Exercise price of warrants (in dollars per share)														$ 2.87
Number of warrants outstanding (in shares)										1,850,000						1,400,000
First Seven Lakhs Shares | Perceptive Credit Agreement
Sale of stock
Common stock that can be purchased with warrants (in shares)										700,000						700,000
Exercise price of warrants (in dollars per share)										$ 3.83	$ 4.67					$ 3.74
Number of warrants outstanding (in shares)										700,000						700,000
Remaining Seven Lakhs Shares | Perceptive Credit Agreement
Sale of stock
Common stock that can be purchased with warrants (in shares)										700,000						700,000
Exercise price of warrants (in dollars per share)										$ 3.11	3.74					$ 4.67
Number of warrants outstanding (in shares)										700,000						700,000
Warrants | Perceptive Credit Agreement
Sale of stock
Common stock that can be purchased with warrants (in shares)										450,000
Exercise price of warrants (in dollars per share)										$ 2.43	$ 2.87
Number of warrants outstanding (in shares)										450,000
2020 Shelf Registration Statement
Sale of stock
Aggregate amount of securities issuable															$ 200,000
Proceeds from issuance of common stock in public offering, net of offering costs	$ 4,300
Conversion price	$ 0.20
Preferred Stock, convertible, shares issuable	24,250,000
Stock stated value	$ 1,000
2020 Shelf Registration Statement | Series A Warrants
Sale of stock
Common stock that can be purchased with warrants (in shares)	24,250,000
Number of warrants outstanding (in shares)	24,250,000
2020 Shelf Registration Statement | Series B Warrants
Sale of stock
Common stock that can be purchased with warrants (in shares)	24,250,000
Number of warrants outstanding (in shares)	24,250,000
2018 Shelf Registration Statement
Sale of stock
Aggregate amount of securities issuable															$ 100,000
Private Placement | Common stock
Sale of stock
Issuance of common stock (in shares)					8,426,750			8,426,750
Share price (in dollars per share)					$ 0.93
Proceeds from issuance of common stock in public offering, net of offering costs					$ 7,800
At-the-market sales | Maximum
Sale of stock
Authorized value for shares issuance																	$ 20,000	$ 10,000
At-the-market sales | Common stock
Sale of stock
Issuance of common stock (in shares)						6,915,151		12,242,436
At-the-market sales | Common stock | Maximum
Sale of stock
Authorized value for shares issuance												$ 50,000
At-the-market sales | Common stock | Maximum | Subsequent event
Sale of stock
Authorized value for shares issuance									$ 50,000
At Market Sales on January 23
Sale of stock
Proceeds from issuance of common stock in public offering, net of offering costs							$ 2,500
At Market Sales on January 23 | Common stock
Sale of stock
Issuance of common stock (in shares)							1,801,528
At Market Sales on November 8
Sale of stock
Proceeds from issuance of common stock in public offering, net of offering costs							$ 19,300
At Market Sales on November 8 | Common stock
Sale of stock
Issuance of common stock (in shares)							10,440,908
At Market Sales on March 18 | Common stock
Sale of stock
Issuance of common stock (in shares)						6,915,151
Proceeds from issuance of common stock in public offering, net of offering costs						$ 9,300
Public offering
Sale of stock
Proceeds from issuance of common stock in public offering, net of offering costs						$ 21,081	$ 48,434	$ 12,687
Public offering | Common stock
Sale of stock
Issuance of common stock (in shares)		26,666,648	17,250,000	14,526,315		26,666,648	17,250,000	14,526,315
Common stock that can be purchased with warrants (in shares)		13,333,324
Common stock that can be purchased with one-half of warrant (in shares)		1
Share price (in dollars per share)		$ 0.85	$ 3	$ 0.95
Proceeds from issuance of common stock in public offering, net of offering costs		$ 21,100	$ 48,400	$ 12,700
Number of warrants outstanding (in shares)		13,333,324
Series A Preferred Stock | 2020 Shelf Registration Statement
Sale of stock
Issuance of common stock (in shares)	2,425
Series B Preferred Stock | 2020 Shelf Registration Statement
Sale of stock
Issuance of common stock (in shares)	2,425

Equity Incentive Plans - Stock

Equity Incentive Plans - Stock Options Summary (Details) - Common stock options	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Minimum
Equity Incentive Plans
Exercise prices of options granted through the end of the year (in dollars per share)	$ 0.58
Maximum
Equity Incentive Plans
Exercise prices of options granted through the end of the year (in dollars per share)	$ 10.75
1997 Plan and 2008 Plan
Equity Incentive Plans
Expiration period	10 years
Vesting period	4 years
2014 Incentive Compensation Plan
Equity Incentive Plans
Shares available for grant | shares	1,507,871

Equity Incentive Plans - Stock-

Equity Incentive Plans - Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Equity Incentive Plans
Total stock-based compensation expense	$ 3,338	$ 2,818	$ 1,762
Assumptions used to compute employee stock based compensation under the Black-Scholes option pricing model
Expected volatility (as a percent)			65.00%
Expected dividend yield (as a percent)	0.00%	0.00%	0.00%
Expected life (in years)	6 years 3 months	6 years 3 months	6 years 3 months
Minimum
Assumptions used to compute employee stock based compensation under the Black-Scholes option pricing model
Risk-free interest rate (as a percent)	0.66%	0.40%	1.74%
Expected volatility (as a percent)	105.00%	65.00%
Maximum
Assumptions used to compute employee stock based compensation under the Black-Scholes option pricing model
Risk-free interest rate (as a percent)	1.51%	1.68%	2.61%
Expected volatility (as a percent)	106.00%	106.00%
Common stock options
Equity Incentive Plans
Total stock-based compensation expense	$ 3,338	$ 2,818	$ 1,762
Unrecorded deferred stock-based compensation
Unrecorded deferred stock-based compensation balance related to stock options	$ 6,400
Weighted-average amortization period over which cost is expected to be recognized	2 years 6 months
Weighted average grant date fair value of options granted (in dollars per share)	$ 2.63
Common stock options | Cost of goods sold
Equity Incentive Plans
Total stock-based compensation expense	$ 271	14
Common stock options | Research and development
Equity Incentive Plans
Total stock-based compensation expense	490	651	522
Common stock options | Selling and marketing
Equity Incentive Plans
Total stock-based compensation expense	148	108
Common stock options | General and administrative
Equity Incentive Plans
Total stock-based compensation expense	2,429	$ 2,045	$ 1,240
Restricted Stock Units
Unrecorded deferred stock-based compensation
Unrecorded deferred stock-based compensation balance related to stock options	$ 250,000,000
Weighted-average amortization period over which cost is expected to be recognized	1 year

Equity Incentive Plans - Stoc_2

Equity Incentive Plans - Stock Option Activity (Details) - Common stock options - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Options
Options outstanding at beginning of year (in shares)	8,519,086	7,192,357
Options granted (in shares)	2,581,647	2,539,403
Options exercised (in shares)	(126,400)	(503,448)
Options cancelled/forfeited (in shares)	(606,891)	(709,226)
Options outstanding at end of year (in shares)	10,367,442	8,519,086	7,192,357
Options exercisable at end of year (in shares)	6,262,675
Vested and expected to vest at end of year (in shares)	10,367,442
Weighted Average Exercise Price
Options outstanding at beginning of year (in dollars per share)	$ 3.13	$ 3.42
Options granted (in dollars per share)	2.63	2.80
Options exercised (in dollars per share)	0.60	1.21
Options cancelled/forfeited (in dollars per share)	6.61	6.20
Options outstanding at end of year (in dollars per share)	2.83	$ 3.13	$ 3.42
Options exercisable at end of year (in dollars per share)	$ 2.99
Weighted Average Remaining Contractual Life (Years)
Options outstanding	7 years 1 month 6 days	7 years 3 months 18 days	7 years 2 months 12 days
Options exercisable	6 years
Estimated stock price (in dollars per share)	$ 0.49

Equity Incentive Plans - Restri

Equity Incentive Plans - Restricted Stock (Details) - Restricted Stock Units - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Shares
Restricted stock outstanding at beginning of year (in shares)	159,795
Granted (in shares)	297,576	159,795
Vested (in shares)	(124,081)
Restricted stock outstanding at end of year (in shares)	333,290	159,795
Weighted Average Grant Date Fair Value
Granted (in dollars per share)	$ 1.68	$ 2.81
Vested (in dollars per share)	2.81
Restricted stock outstanding at end of year (in dollars per share)	$ 1.80
Aggregate Intrinsic Value
Intrinsic value of vested shares	$ 163	$ 458
Employee
Shares
Granted (in shares)	70,923
Vesting period	1 year
Executive officers
Shares
Granted (in shares)		52,651
Vesting period		1 year
Directors
Shares
Granted (in shares)	226,353	107,144
Directors | Minimum
Shares
Vesting period	1 year	1 year
Directors | Maximum
Shares
Vesting period	3 years	3 years

Equity Incentive Plans - Perfor

Equity Incentive Plans - Performance Based Restricted Stock Awards (Details) - 2014 Incentive Compensation Plan - Performance Units - Executive officers - shares	1 Months Ended	12 Months Ended
	Jan. 31, 2018	Dec. 31, 2018	Dec. 31, 2021	Dec. 31, 2019
Equity Incentive Plans
Shares granted	365,000
Shares cancelled		50,000
Shares outstanding		315,000	0	315,000

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income Loss Net of Tax [Abstract]
Balance at beginning of the period	$ 3
Other comprehensive income of unrealized gain on marketable securities	$ (3)	$ 3
Balance at end of the period		$ 3

Income Taxes - Summary (Details

Income Taxes - Summary (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Taxes
Corporate tax rate (as a percent)	21.00%	21.00%	21.00%
Federal | Net Operating Losses
Income Taxes
Net operating loss carryforwards	$ 347.6			$ 194
Indefinite net operating loss carryforward	154
Federal | Research and Development.
Income Taxes
Tax credit carryforwards	6.4
State | Net Operating Losses
Income Taxes
Net operating loss carryforwards	116
State | Research and Development.
Income Taxes
Tax credit carryforwards	$ 1.9

Income Taxes - Deferred Taxes (

Income Taxes - Deferred Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Net operating loss carryforwards	$ 81,102	$ 66,907
Research credit carryforward	7,943	7,909
Stock options and other	2,114	1,962
Total gross deferred tax assets	91,159	76,778
Valuation allowance for deferred tax assets	(91,159)	(76,778)
Net deferred tax assets	0	0
Valuation allowance
Increase (decrease) in the valuation allowance	$ 14,400	$ 10,600

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Reconciliation of the U.S. statutory income tax rate to the Company's effective tax rate
Federal income tax at statutory rate (as a percent)	21.00%	21.00%	21.00%
State income tax benefit, net of federal benefit (as a percent)	0.30%	1.00%	7.00%
Research and development tax credits (as a percent)	0.20%	0.70%	4.00%
Other (as a percent)	(2.20%)	(2.00%)	(4.00%)
Increase to valuation allowance (as a percent)	(19.30%)	(20.70%)	(28.00%)
Effective income tax rate (as a percent)	0.00%	0.00%	0.00%

Income Taxes - Sale of New Jers

Income Taxes - Sale of New Jersey Net Operating Losses (Details) - USD ($) $ in Millions	1 Months Ended
	Jan. 31, 2021	Jan. 31, 2018	Dec. 31, 2021
Sale of New Jersey Net Operating Losses
Additional cash benefit			$ 4.7
Sale of unused NOLs | New Jersey
Sale of New Jersey Net Operating Losses
Maximum lifetime benefit under the Program	$ 20	$ 15
Sale of unused NOLs | New Jersey | Minimum
Sale of New Jersey Net Operating Losses
Allowable sale of unused tax benefits as a percentage of total value		80.00%

2019 Retention Plan (Details)

2019 Retention Plan (Details) - USD ($) $ / shares in Units, $ in Millions	Jul. 03, 2019	Dec. 31, 2021	Feb. 29, 2020
2019 Retention Plan
Cash portion of the retention plan			$ 0.3
Options granted In January 2019 | Vesting on December 31, 2020
2019 Retention Plan
Percentage of options to vest	25.00%
Options granted In January 2019 | Vesting on January 29, 2020
2019 Retention Plan
Percentage of options to vest	50.00%
Options granted In January 2019 | Vesting on June 30, 2020
2019 Retention Plan
Percentage of options to vest	25.00%
Options granted in July 2019
2019 Retention Plan
Stock option exercise price (in dollars per share)		$ 1.48
Options granted in July 2019 | Vesting on July 3, 2020
2019 Retention Plan
Percentage of options to vest		50.00%
Options granted in July 2019 | Vesting on December 31, 2020
2019 Retention Plan
Percentage of options to vest		50.00%

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	Dec. 31, 2021USD ($)
Commitments and Contingencies
Future purchase commitments	$ 5.2

Subsequent Event (Details)

Subsequent Event (Details) - USD ($)

Mar. 14, 2022

Mar. 13, 2022

Jan. 07, 2022

Oct. 08, 2021

Feb. 21, 2020

Aug. 31, 2019

Mar. 31, 2019

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

Jan. 06, 2022

Oct. 31, 2021

Feb. 28, 2021

Subsequent Event [Line Items]

Common stock that can be purchased with warrants (in shares)

13,333,324

450,000

Common Stock, Shares Authorized

150,000,000

150,000,000

2020 Shelf Registration Statement

Subsequent Event [Line Items]

Proceeds from issuance of common stock in public offering, net of offering costs

$ 4,300,000

Stock stated value

$ 1,000

Conversion price

$ 0.20

Preferred Stock, convertible, shares issuable

24,250,000

2020 Shelf Registration Statement | Series A Warrants

Subsequent Event [Line Items]

Common stock that can be purchased with warrants (in shares)

24,250,000

2020 Shelf Registration Statement | Series B Warrants

Subsequent Event [Line Items]

Common stock that can be purchased with warrants (in shares)

24,250,000

2020 Shelf Registration Statement | Series A Preferred Stock

Subsequent Event [Line Items]

Issuance of common stock (in shares)

2,425

2020 Shelf Registration Statement | Series B Preferred Stock

Subsequent Event [Line Items]

Issuance of common stock (in shares)

2,425

Private Placement | Common stock

Subsequent Event [Line Items]

Issuance of common stock (in shares)

8,426,750

8,426,750

Share price (in dollars per share)

$ 0.93

Proceeds from issuance of common stock in public offering, net of offering costs

$ 7,800,000

At-the-market sales | Common stock

Subsequent Event [Line Items]

Issuance of common stock (in shares)

6,915,151

12,242,436

At Market Sales on January 23

Subsequent Event [Line Items]

Proceeds from issuance of common stock in public offering, net of offering costs

$ 2,500,000

At Market Sales on January 23 | Common stock

Subsequent Event [Line Items]

Issuance of common stock (in shares)

1,801,528

At Market Sales on November 8

Subsequent Event [Line Items]

Proceeds from issuance of common stock in public offering, net of offering costs

$ 19,300,000

At Market Sales on November 8 | Common stock

Subsequent Event [Line Items]

Issuance of common stock (in shares)

10,440,908

At Market Sales on March 18 | Common stock

Subsequent Event [Line Items]

Issuance of common stock (in shares)

6,915,151

Proceeds from issuance of common stock in public offering, net of offering costs

$ 9,300,000

Public offering

Subsequent Event [Line Items]

Proceeds from issuance of common stock in public offering, net of offering costs

$ 21,081,000

$ 48,434,000

$ 12,687,000

Public offering | Common stock

Subsequent Event [Line Items]

Issuance of common stock (in shares)

26,666,648

17,250,000

14,526,315

26,666,648

17,250,000

14,526,315

Common stock that can be purchased with warrants (in shares)

13,333,324

Share price (in dollars per share)

$ 0.85

$ 3

$ 0.95

Common stock that can be purchased with one-half of warrant (in shares)

1

Proceeds from issuance of common stock in public offering, net of offering costs

$ 21,100,000

$ 48,400,000

$ 12,700,000

Subsequent event

Subsequent Event [Line Items]

Common Stock, Shares Authorized

300,000,000

150,000,000

Subsequent event | Perceptive Credit Agreement

Subsequent Event [Line Items]

Repayments of Debt

$ 5,000,000

Debt Instrument, Prepayment Premium Due

$ 0

Subsequent event | Series A Warrants | Securities Purchase Agreement

Subsequent Event [Line Items]

Common stock that can be purchased with warrants (in shares)

24,250,000

Warrants and rights outstanding, term

5 years

Stock stated value

$ 1,000

Conversion price

$ 0.20

Preferred Stock, convertible, shares issuable

24,250,000

Exercisable term

6 months

Exercise price of warrants (in dollars per share)

$ 0.26

Subsequent event | Series B Warrants | Securities Purchase Agreement

Subsequent Event [Line Items]

Warrants and rights outstanding, term

1 year 6 months

Proceeds from issuance of common stock in public offering, net of offering costs

$ 4,900,000

Exercisable term

6 months

Exercise price of warrants (in dollars per share)

$ 0.26

Subsequent event | Series A Preferred Stock | Securities Purchase Agreement

Subsequent Event [Line Items]

Issuance of common stock (in shares)

2,425

Subsequent event | Series B Preferred Stock | Securities Purchase Agreement

Subsequent Event [Line Items]

Issuance of common stock (in shares)

2,425